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There are several natural biological products, which are effective to trigger immune 
responses in animals and human beings. In this regard, various plant species are considered 
to be potent natural biological products and their efficacy has been reported in various animal 
models. In the present study, Aloe (A.) vera derived biomolecules including polysaccharides 
and proteins were isolated and characterized as biological response modifiers and their 
subsequent protective effects against coccidiosis in chickens. A total of 640 chicks were 
randomly divided into two main treatment groups namely A (polysaccharides) and B 
(proteins), each containing 320 chicks. Each group was administered orally with the graded 
doses of polysaccharides and proteins for three consecutive days i.e. day 5 th, 6th and 7th of 
age.  Cellular immune responses were assessed for in vivo and in vitro lymphoproliferative 
responses to Phytohemagglutinin-P (PHA-P), Concanavalin-A (Con-A) respectively and 
Carbon particle clearance assay. Humoral immune responses were detected by microplate 
haemagglutination assay on 7th and 14th days post primary and secondary injections of sheep 
red blood cells. Weekly weight gains and feed conversion ratios were also calculated. For 
therapeutic studies chickens were challenged with mixed Eimeria species on 14th day post 
administration of A. vera biomolecules. Results revealed significantly higher (p<0.05) 
lymphoproliferative response to PHA-P and Con-A in chickens administered with A. vera 
biomolecules as compared to control. Carbon particle clearance assay showed significantly 
higher clearance index (K) in control group than all biomolecules administered groups and 
phagocytic index (α) showed significantly higher response in all three biomolecules 
administered groups as compared to control. Significantly higher total Igs, IgG and IgM titers 
were also detected in groups administered with A. vera biomolecules. Biomolecules 
administered chickens showed better feed conversion ratios and significantly higher (p<0.05) 
weekly weight gains as compared to control. In challenge experiment maximum protection 
70% and 57.5% were observed in polysaccharides and proteins administered groups, 
respectively. Significantly lower oocysts per gram of droppings, lesser lesion scores, better 
weight gains and higher anticoccidial index were observed in biomolecules administered 
groups. From the current study, it was concluded that A. vera derived biomolecules have the 
potential to be used as immunotherapeutic agent(s) in poultry and can be commercialized. 
ABSTRACT 
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CHAPTER 1  
INTRODUCTION  
 
 The use of plants as therapeutic agents has a long traditional history; although 
isolation of their active compounds did not gain much attention till 19th century (Phillipson 
and Anderson, 2001). According to World Health Organization, 80% population of world 
used herbal medicines for differnt human diseases (Serrentino, 1991). In this regard, many 
plants and their constituents including Angelica gigas, Cissampelos pareira, Astragalus 
membranaceus, Mangifera indica, Ganoderma lucidum, Ocimum sanctum, Zingiber 
officinale, Phyllanthus emblica, Allium sativum, Curcuma longa, Nyctanthus arbor-tritis, 
Saccharum officinarum and Aloe vera (Minja, 1989; Waller et al., 2001; Fajimi and Taiwo, 
2005; Githiori et al., 2006; Athanasiadou et al., 2007; Awais et al., 2011; Akhtar et al., 2012; 
Awais et al., 2013) have been reported for different medicinal properties. 
Among these, Aloe (A.) vera (Aloe barbadensis Miller) is the most commonly used 
medicinal plant having historical importance. It is a succulent plant found in tropical and 
subtropical areas of many continents including Pakistan. Modern therapeutic use of A. vera 
started in 1920s and now it is found in many journals, topic of numerous researches and 
commercial literature on internet. It has been reported to cure variety of conditions including 
mild fever, burns, wounds, gastrointestinal disorders, sexual vitality, fertility problems, 
inflammation, arthritis, cancer, and acquired immunodeficiency syndrome (Bashir et al., 
2011; Manvitha and Bidya, 2014). Now a day, A. vera is extensively used in many 
manufacturing industries of foods, pharmaceuticals and cosmetics (Yang et al., 2003). 
A. vera is unique in nature having many biological active components including 
proteins, carbohydrates, vitamins, enzymes, minerals, sugar, lignin, saponins and salicylic 
acids (Surjushe et al., 2008). These compounds have numerous pharmacological activities 
including wounds healing, antinflammatory, antiarthritis, antioxidative, antidiabetic and 
anticarcinogen (Waihenya et al., 2002; Saritha et al., 2010; Iji et al., 2010).  
A. vera polysaccharides, anthraquinones and lectins have immunomodulatory effects 
(Leung et al., 2004; Akev et al., 2007; Liu and Wang, 2007). Its immunomodulatory 
activities include stimulation of macrophages, which produced nitric oxide and thus showed 
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effects on the antigen presenting cells (APC) to release cytokine(s) (Strickland, 2001). The 
most important component of A. vera gel is acemannan (a linear carbohydrate polymer 
containing acetylated mannose). It is a storage polysaccharide, present in parenchyma 
protoplast (Rodriguez et al., 2010) and has potential to act against viral infections, which 
reduced opportunistic infections and stimulate wound healing (Ni et al., 2004; Christiaki and 
Florou-Paneri, 2010). Its immunomodulatory effects had been reported in different animal 
models (Krishnan, 2006). It stimulates the natural and adaptive defense mechanism(s) 
including cytokines and help the body to protect itself (Alamgir and Uddin, 2010). Due to its 
biological response modifying activities it shows beneficial prophylactic and therapeutic 
effects against pathogens. It can be successfully used in oncology, inflammatory diseases, 
transplantation medicine and autoimmune disorders. Many types of colony stimulating 
factors, interferons, monoclonal antibodies, interleukins, tumor necrosis factor and 
erythropoietin are also being used as biological response modifiers (immunomodulators); 
body can produce them but in small quantity (Murthy et al., 2010). These can be prepared 
from certain species of plants, fungi (cell wall and cytoplasm) and bacteria (cell wall 
lipopolysaccharides); although they are not successfully used (Leung et al., 2004).    
As far as therapeutic efficacy of A. vera and its component(s) is concerned, it had 
been reported in  different animal models and human beings with promising results 
(Strickland, 2001; Agarry et al., 2005), although limited work had been conducted on poultry 
(Mwale et al., 2006; Djeraba and Quere, 2000; Akhtar et al., 2012). Keeping in view the 
diverse biological functions of A. vera, the present study was conducted with following 
objectives: 
1.  Isolation and characterization of A. vera biomolecules including polysaccharides and 
proteins  
2.  Evaluation as biological response modifiers in terms of cellular and humoral immune        
responses in chickens  
3.  Assessment of their immunotherapeutic effects against avian coccidiosis in chickens.  
The general objectives of these studies were to investigate the potential of A. vera 
biomolecules as alternative therapeutic and immunomodulatory agents in chickens. 
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Aloe (A.) vera is a hard, tropical, perennial, succulent, xerophytic and drought 
resistance plant (Surjushe et al., 2008; Ernst, 2000; Manvitha and Bidya, 2014). It belongs to 
kingdom Plantae, order Asparagales, family Liliaceae/Asphodelaceae and genus Aloe 
(Agarwal and Sharma, 2011). More than 500 species of A. vera has been reported so far 
among, which A. vera is most common (Bawankar et al., 2012).  
The height and weight of mature A. vera plant (4-6 years old) ranges from 80-100 cm 
and 1.5-2 kg respectively. Under favorable conditions, it can survive for more than 50 years 
(Sharma et al., 2012). A. vera flowers are yellow tubular and fruit contains many seeds 
(Shelton, 1991). It has long, triangle, spiked and fleshy leaves, which has 20 inches length 
and 5 inches width (Moghaddasi and Verma, 2011). The leaves are made of three layers, 
upper layer termed as rind that synthesizes proteins and carbohydrates and have xylem, 
phloem and vascular bundles for transporting substances (water and starch). Lower layer 
termed as sap that contains bitter fluid, which protect it from being consumed by animals. 
Middle layer contains bitter yellow substance containing glycosides and anthraquinones. 
Inside these layers, a jelly like substance named mucilage gel is present. It is a clear 
substance made of 99 per cent water and glucomannans, vitamins, lipids, aminoacids and 
sterols (Balasubramanian and Narayanan, 2013). 
 Owing to variety of medicinal uses, A. vera is commonly known as Barbados Aloe, 
burn plant, Chinese Aloe, first aid plant, lily of desert, Indian Aloe, medicine plant and true 
Aloe (Liao et al., 2004). The synonyms are Aloe barbadensis Miller, A. elongate Murray, A. 
vera L chinensis Berger, A. rubescens DC, A. vulgaris Lam, A. indica Royle, A. perfoliata L. 
var. (Newton, 1979). The name of A. vera is driven from two words alloeh and vera; alloeh 
means shining bitter substance and vera means true (Surjushe et al., 2008; Joseph and Raj, 
2010). Mostly, its four species are commonly used for medicinal purposes including Aloe 
barbadensis Miller (Chandana et al., 2007), Aloe arborescens (Morita et al., 2007), Aloe 
ferox (Zahn et al., 2007) and Aloe perryi baker (Eshun and He, 2004). Commercially Aloe 
barbadensis Miller and Aloe arborescens are grown today (Manvitha and Bidya, 2014).  Of 
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these two, Aloe barbadensis Miller (Aloe vera) is most commonly used and studied species 
due to its diverse clinical efficacy against various health conditions including laxative, 
analgesic, antifungal, antitumour, antibacterial, immunomodulator, antidiabetic etc (Biswas 
and Mukherjee, 2003).  
Summarizing these reports, A. vera is a plant of medicinal importance. Plants have 
become major basic source for new medicines, due to increased knowledge of their 
composition. About 25% medicines are plant origin (Irshad et al., 2011). Plants also have 
comparatively low adverse reactions as compared to conventional chemical based medicines 
(Ahmed and Hussain, 2013). Moreover, its juice has proven to be nontoxic (Manvitha and 
Bidya, 2014). 
2.1: History of medicinal uses of Aloe vera 
 A. vera use as medicinal plant is as old as history of man. Mesopotamians and 
Egyptians had been using this plant since 1750 BC (Shelton, 1991). It has a traditional role in 
medicine like Ayurveda, Unani, Siddha and homeopathy. It has been used as medicine in 
many cultures from millennia including Egypt, China, India, Mexico, Greece and Japan. 
Greek scientists considered it a universal panacea and Egyptians regarded it as immortality 
plant (Marshall, 1990). 
 The famous beauty queens of Egypt Cleopatra (69-30 BCE) and Nefertiti (1353 BCE) 
used A. vera in their beauty products (Haller, 1990; Manvitha and Bidya, 2014). According 
to Bible, Jesus covered his hand with A. vera for soothing the pain and wound healing when 
he was hung on the cross. Arab physicians and Hippocrates also used it. Spanish explorers 
brought A. vera to western hemisphere. The Alexander the Great (333 B.C.) occupied Indian 
island named Socotra to secure A.vera supply, which was used to treat wounded soldiers. Its 
first English reference was translated by John Goodyew AD. 1655 Dioscorides Medical 
treatise De Materia Medica (Surjushe et al., 2008). The old well known physicians like 
Galen, Dioscsordes, Charaka and Surushta used A. vera in their medicines. In early 1800, it 
has been used as a laxative throughout United States.  In 1930, it gained popularity in United 
States as it was used to treat X-ray burns (Rowe et al, 1941; Tyler et al., 1981). It was 
reported as a medicine in 1935 (Collin and Collin, 1935). Crewe used its gel locally for 
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treating pruritus vulvae and eczema in 1937 and found very effective. A. vera was also 
reported an effective agent against thermal burns in combination with mineral oil (Crewe, 
1939). Its pulp was used for treating ulcers induced by radiation, which increased healing rate 
(Rowe et al., 1941). Barnes (1947) used its leaves with petrolatum for treating finger 
abrasions. The results showed that A. vera healed better than petrolatum mixed base (Barnes, 
1947). In 1953, Lushbaugh and Hale studied its effects on beta irradiation induced wounds in 
rabbits. Histopathology of lesions showed a rapid healing of treated sites by increasing repair 
and degeneration rate. The treated wounds also have more collagen deposition (Lushbaugh 
and Hale, 1953). History of A. vera use has been summarized in table 2.1. 
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Table 2.2: A tabulated presentation of history of medicinal uses of Aloe vera 
Era/Year Scientist/Researcher/Publications Medicinal uses 
50 B.C. Celsius     Laxative  
41-68 A.D. Greek Herbal book  Wound healing  
 Heals tonsil 
 Sleep inducing agent 
 Boils treatment 
 Prevents hair loss 
 Cleanses stomach 
 Mouth and eye diseases  
200  European physicians Aretaces, 
Galen and Antyllus   
 Medicinal plant for clinical 
purposes 
700-800  Chinese   Fever 
 Convulsions 
 Sinus treatment 
1300-1500  English   Purgative 
 Wound healing  
1700-1900  In 1720, Carl Von Linne  
Written in pharmacopeia of United 
States in 1820. 
 Skin protecting agent 
 Purgative 
 Ulcers, dermatitis, radiation injuries 
and burns 
1950  Amico and Luisa  Antibiotic property 
1975  Galal et al.  Skin allergies 
 Cyst inflammation 
 Abscesses 
 Laceration 
1979  Suzuki et al.  Mitogenic activity 
 Hemagglutination activity 
1985  
 
Bland   Indigestion 
 Infections 
1987  Davis et al.  Wound healing 
1992  Swaim et al.  Antibiotic activity 
 Wound healing 
1994  Koo  Antiulcer  
 Antidiabetic  
1997   Yagi et al.  Propagation and cellular growth of 
normal human dermal cells 
2000  Pecere  Antineuroectodermal action in vivo  
and in vitro 
2001  Yagi et al. 
 
 Wound healing 
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2002  Choi et al. 
 
 Angiogenic effect on embryonic 
chorioallantoic membranes 
 Reduced treatment related side 
effects 
2003  Singh et al.  Liver diseases  
 Improve liver enzymes function, 
helpful in carcinogen metabolism  
2004 Talmadge et al. 
Rajasekaran et al. 
 Hematopoietic and hematologic 
activity regulation of liver lung 
cytokines levels  
 Carbohydrate metabolizing 
enzymes regulation 
 Glucose homeostasis 
2005 Paulsen et al.  Significantly reduced psoriasis 
lesions including erythema  
2006 Davis and Rosenthal 
Mwale et al. 
 Gel topical and oral administration 
has anti-inflammatory effect 
 against avian coccidiosis 
2007 Vaidya and Devasagayam 
Bajwa et al. 
 Antioxidant activity 
 Antimicrobial activity 
2008 He and Wang 
Madan et al. 
 Proliferation of stem cells  
 increased white blood cells 
2009 Takahashi et al. 
 
 
 Skin wounds  
 Immunomodulatory effect 
2010 Kim et al.  Increased levels of  
immunoglobulin E and 
inflammatory cytokines in 
spontaneous atopic dermatitis 
2011 Das et al. 
 
 Antiinflammatory and antifungal 
properties 
 
2012 
 
Akhtar et al. 
Kedarnath et al. 
Halder  et al. 
 Immunomodulator  
 Immunotherapeutic efficacy against 
coccidiosis in chickens 
 Antifungal agent 
 Antimicrobial agent 
2013 Thu et al. 
Arora et al. 
 Antimicrobial agent 
 Antimycoplasmic agent 
2014 Suganya et al. 
Ibe et al. 
  Antiinflammatory 
 Antioxidant 
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2.2: Constituents of Aloe vera 
The leaves of A. vera have a yellow sap called Aloin, which is used by 
pharmaceutical industry as an active ingredient for laxative medicines. The intact fleshy part 
(inside leaf) contains cell walls and organelles, and is called parenchyma tissue or pulp. The 
other component is gel or mucilage. It is a clear viscous, semisolid, transparent and colorless 
gel inside the parenchyma tissues and is a main component of various skin products as 
moisturizer and nutritional agent since early 50s (Ni and Tizard, 2004). 
 A. vera plants contain more than 75 bioactive compounds, usually present in its gel 
and latex (Eshun and He, 2004; Joseph and Raj, 2010; Ajmera et al., 2014). Gel is mainly 
water (about 99%) and remaining portion contains monosaccharides (mannose-6-phosphate) 
and polysaccharides (gluco-mannans) (Shelton, 1991). It also contains a major glucomannan 
named as acemannan (commercially available), glycoprotein named alprogen (antiallergic) 
and C-glucosyl chromone (anti-inflammatory) (Hutter and Salmon, 1996; Ro et al., 2000). 
 A. vera gel extract contains 38% carbohydrates containing 4% glucose, 41% 
galacturonic acid, 6% xylose, 39% mannose, 1% rhamnose, 6% galactose, 1% fucose, 1% 
arabinose and 2% proteins (Luta et al., 2009; Marzorati et al., 2010). It contains eight 
essential amino acids, which are protein building blocks and influence the functioning of 
brain. Human body needs 22 amino acids, which can be synthesized except 8 essential amino 
acids, acquired through daily food intake. These all essential amino acids are present in A. 
vera including valine, isoleucine, methionine, tryptophan, leucine, threonine, phenylalanine, 
and lysine. Moreover, non-essential amino acids including aspartic acid, alanine, glutamine, 
arginine, tyrosine, serine, asparagines, histidine, cysteine, glutamic acid, glycine and proline 
are also present in the A. vera (Moghaddasi and Verma, 2011). 
 Phytochemicals present in A. vera include lectins, acetylated mannans, 
anthraquinones, C-glycosides, emodin, anthrones and polymannans (King et al., 1995; 
Boudreau and Beland., 2006); whereas, its qualitative phytochemical analysis have evinced 
presence of flavonoids, saponins, resins, tannins, glycosides, acidic compounds, 
anthraquinone and terpenoids. A. vera gel also contains sterols, reducing sugars and 
carbohydrates (Mariappan and Shanthi, 2012).  
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 A. vera is also a natural source of vitamins A, B12, C, E, folic acid, thiamine and 
niacin. Minerals present in it are chromium, sodium, calcium, potassium, iron, magnesium, 
copper, manganese and zinc (Shelton, 1991). Glycosides named anthraquinones and aloin (A, 
B) are rich in A. vera latex (Tyler, 1994). Twelve different anthraquinones are present in A. 
vera and the most important are aloin and emodin, which have analgesic, antibacterial and 
antiviral activities. These compounds aid in breaking dead cells and resultant cell residues 
attract blood to the affected area and expel materials from ulcers and wounds. Recently, 
eighteen phenolic compounds had been isolated and identified from A. vera by reverse phase 
high performance liquid chromatography (HPLC) (Lopez et al., 2013).  
 Enzymes mainly present in A. vera are amylase, which degrades starches and sugars; 
bradykinase have analgesic, immunostimulant, and anti-inflammatory effects; creatinine 
phosphokinase effects on metabolism; cellulase digests cellulose; lipase digests fats and 
catalase avoids water accumulation in body and proteolyase causes hydrolysis of proteins 
into its constituents. Alkaline phosphatase, oxidase and carboxypeptidase present in A. vera 
act as biochemical catalysts. Enzymes also enable body cells to work efficiently (Nandal and 
Bhardwaj, 2012). A. vera contains proteolytic enzymes named glutathione peroxidase, 
carboxypeptidase and many isozymes of superoxide dismutase (Klein and Penneys, 1988; 
Sabeh et al., 1996). 
 The most important component of A. vera gel is acemannan (a linear polymer 
containing acetylated mannose). It is a storage polysaccharide (average molecular weight of 
1000kDa) and present in parenchyma protoplast (Femenia et al., 1999; Rodriguez et al., 
2010). It act as immunomodulator, antiviral, reduces opportunistic infections and stimulates 
healing (Ni et al., 2004; Christiaki and Florou-Paneri, 2010). HPLC analysis of gel and leaf 
extract showed presence of chromones, glucomannose, vitamin C, 
galactoglucoaralimannone, anthraquinone, gluconic acid and phenols (Mariappan and 
Shanthi, 2012). 
 Different constituents isolated from A. vera in several studies along with their 
pharmacological activities are summarized in table 2.2.  
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Table 3.2: A tabular presentation of Aloe vera constituents and their          
        pharmacological activities 
Constituents Processig 
type 
Types of constituents 
(compounds) 
General activities Reference 
Carbohydrates  Gel  Acetylated mannan 
 Acetylated glucomannan 
 Glucogalactomannn 
 Pure mannan 
 Xylan 
 Galactogalacturan 
 Galactan 
 Arabinogalactan 
 Cellulose 
 Pectic substances 
 Hemicellulose 
 Arabinan 
 Arabinorhamnogaln 
 Glucuronic acid 
Antiallergic 
Antiinflammatory 
Immunomodulation 
Ni et al., 
2004; 
Jani et al., 
2007 
 
Proteins  Leaf   Aloctin A & B 
 ATF 11 
 Salicylic acid 
 
Antibacterial 
Antiinflammatory  
Hemagglutination  
Ni and Tizard, 
2004;  
Davis and 
Maro, 1989 
Aminoacids  Leaf   Eight essential amino 
acids including 
 Valine 
 Isoleucine 
 Methionine 
 Tryptophan 
 Leucine 
 Threonine 
 Phenylalanine 
 lysine.  
enzyme production 
Muscle building 
Agarwal and 
Sharma, 2011 
Enzymes Leaf  Alkaline phosphatase 
 Peroxidase 
Improve digestion 
Antiinflammatory 
Obata, 1993; 
Shelton, 1991; 
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 Catalase 
 Aliiase 
 Lipase 
 Cellulase 
 Carboxypeptidase 
 Amylase 
 
Balance stomach 
pH  
Ro et al., 
2000; Nandal 
and Bhardwaj, 
2012 
Vitamins Gel  A, B, C, E, F, Folic acid 
and choline but vitamin 
D is not present 
Red blood cells 
production and 
development  
Amino acids 
metabolism  
Antioxidants 
Surjushe et 
al., 2008; 
Agarwal and 
Sharma, 2011; 
Moghaddasi 
and Verma, 
2011 
Anthraquinons  Rind  
Latex  
Sap 
 12 anthraquinones 
present 
 Anthrol 
 Isobarbaloin 
 Barbaloin 
 Arborescens 
 Emodin 
 
Laxative 
Antibacterial 
Pain killer 
Antifungal 
Analgesic 
Antibacterial 
Antiviral 
Antitumor 
Mckeon,1987;  
Lee et al., 
2001; Yang et 
al., 2003; Yeh 
et al., 2003; 
Davis and 
Rosenthal, 
2006 
Hormones 
 
Gel  Gibberellins 
  Auxins 
Antiinflammatory 
wound healing 
Surjushe et 
al., 2008 
Chromones  Leaf   8-C-glucosyl-(2’-O-
cinnamoyl)-7-O-
methylaloediol A 
 8-C-glucosyl-(S)-aloesol 
 8-C-glucosyl-7-O-
methyl-(S)-aloesol 
 8-C-glucosyl-7-O-
methylaloediol 
Anti-tyrosine 
activity 
Okamura et 
al., 1998; 
Hamman, 
2008 
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 8-C-glucosyl-noreugenin 
 isoaloeresin D 
 isorabaichromone 
 neoaloesin A 
Sugars  Gel   Monosaccharides 
including glucose and 
fructose 
 Polysaccharides 
including glucomannans  
and polymannose 
Antiviral 
Immunomodulator 
Antiinflammatory 
Nandal and 
Bhardwaj, 
2012 
Sterols 
Steroids  
Gel  Cholesterol 
 Lupeol 
 Campesterol 
 Sitosterol 
Antiseptic 
Analgesic activities 
Antiinflammatory 
Edema reduction 
Saritha and 
Anilakumar., 
2010; 
Nandal and 
Bhardwaj, 
2012 
Saponins  Leaf  Glycosides  Antiseptic 
CNS depressant 
Narsih et al., 
2012 
Minerals Gel  Calcium 
 Zinc 
 Magnesium 
 Chromium 
 Iron 
 Potassium 
 Manganese 
 Copper 
 Sodium. 
Metabolic function 
of many enzymes 
Antioxidants 
 
Surjushe et 
al., 2008 
Salicylic acid Gel  Salicylic acid  Analgesic 
Antipyretic effects 
Nandal and 
Bhardwaj, 
2012 
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Phenolic 
compounds  
Flower   Gentisic acid 
 Quercitrin 
 Epicatechin 
Antibacterial 
Antimycoplasmic  
Lopez et al., 
2013 
 
Miscellaneous 
compounds 
Leaf 
Peel 
 
 Arachidonic acid 
 γ-linolenic acid 
 Uric acid 
 Potassiumsorbate  
 Triglicerides 
 Carvone 
 Squalene 
 Limonene 
 Comaric 
 7-tetradecane 
 n-hexadecanoic acid 
 Eicosane 
 Shelton, 1991; 
Narsih et al., 
2012 
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2.3: General uses of Aloe vera 
 The use of A. vera is common in many manufacturing industries of foods (drinks, 
jellies), medicines (pills, capsules), cosmetics and insecticides (Yang et al., 2003). Cosmetics 
include makeup, shampoo, soaps, moisturizers, sunscreens, shaving cream, sprays, lotions, 
creams and lip balms. It can penetrate deeply into dermal layers. Its gel has same antiaging 
effect as vitamin A (Danhof, 1993). Its juice contain oligoelements (manganese and 
selenium) act as antioxidant and antiaging agent, which strengthen cells to combat negative 
effects of oxygen and radiations. Daily gel application on skin has shown refreshing, 
regenerative, cleansing, blood supply stimulation, oxygenation and toxins elimination effects, 
which results smooth, elastic and moisturized skin (Byung, 1993). A. vera is also helpful to 
solve hair problems like hair loss and scalp. Its pH (6) is close to skin pH so it allows easy 
penetration in skin, which strengthens hair follicle and promotes hair growth. Bathfoam 
containing A. vera has reported superior cleansers, leave protective film on skin, which 
prevent dirt invasion and gives pleasant, clean and fresh sensation. Presently, A. vera is most 
widely and actively used ingredient in sun blocks skin preparations and cosmetics (Grindlay 
and Reynolds, 1986). 
                 It is used as water conservator in small animal farms. It also played a role in fresh 
food preservation (Serrano et al., 2006). A. vera consumed along with vitamins C and E has 
improved their absorption for maximum 2-4 hours more than control. It has slowed vitamins 
absorption and they remained on plasma membranes for long time. It is only supplement, 
which increased absorption of these vitamins and also complement them (Vinson et al., 
2005). It has unique benefits including penetration (ability to reach deepest layers of body 
tissues), cleanses (normalizes and detoxifies body metabolism) antiseptic (six agents to kill 
viruses, bacteria and fungi), stimulate cell growth and settle nerves by clearing effect on 
nervous system (Manvitha and Bidya, 2014). A. vera even in higher doses trials on rats, dogs 
and mice has showed no signs of intoxication or death. Its extract containing acemannan (at 
the dose rate of 2,000 mg/kg/day) to Beagle dogs for 6 consecutive months remained 
innocuous without any toxicity (Fogleman et al., 1992). 
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Table 2.4: Tradional medicinal uses of Aloe vera in Ayurveda 
Medicinal uses References 
Healing (Yim et al., 2011; Hamman, 2008) 
Inflammation  (Langmead et al., 2004; Sahu et al., 2013) 
Dermatitis (Olsen et al., 2001; Kim et al., 2010) 
Arthritis (Joseph and Raj, 2010; Kaur et al., 2012) 
Bacterial infections (Waihenya et al., 2002; Agarry et al., 2005) 
Viral infection (Sheets et al., 1991; Lee et al., 2001) 
Fungal infections (Rodriguez et al., 2005; Das et al., 2011) 
Parasitic infections (Dutta et al., 2008; Akhtar et al., 2012) 
Anti-oxidant (Lopez et al., 2013; Ibe et al., 2014) 
Cancers (El-Shemy et al., 2010; Harlev et al., 2012) 
Diabetes mellitus (Yagi et al., 2009; Agarwal and Sharma, 2011) 
HIV (McDaniel et al., 1990; Urch and David, 1999) 
Constipation (Ishii et al., 1994; He and Wang, 2008) 
Hepatitis (Neall, 2004; Bottenberg et al., 2007) 
Heart diseases (Balch and James, 2000; Verma et al., 2013) 
Antiseptic (Surjushe et al., 2008; Jain and Rai, 2014) 
Immunomodulation (Ro et al., 2000; Akhtar et al., 2012) 
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2.4: Aloe vera as a biological response modifier and immunotherapeutic        
 agent 
 Immune system involves several organs having complex cascade of mechanisms to 
protect against diseases. Biological response modifiers (BRMs) mean to modulate these 
immune mechanisms by using various synthetic or natural substances. Phytotherapeutic 
substances provide an alternative to conventional chemotherapy for several diseases, 
especially when host defense activation is required either in case of impaired immune 
response against any disease, or an immunosuppression required against autoimmune 
disorders. These phytotherapeutic agents have been advocated as promising alternatives to 
antibiotic therapy in many disease conditions. Several different types of BRMs 
(immunomodulators) have been identified so far, including natural sources (plants) and 
purified from different microorganisms. They may be defined as any substance of biological 
or synthetic origin, which can modulate, stimulate or suppress any of the components of 
innate or adaptive arms of the immune system (Kumar et al., 2012). Immunology is the most 
important developing area of medical research. It plays a basic role in prevention and 
treatment of various diseases including central organs, digestive tract, skin, respiratory 
system and joints. Presently infectious diseases are considered as immunological disorders. 
Immunomodulators are playing a central part in 21st century medicines. They normalize 
weak/overactive immune system (Patil et al., 2011). 
 Various constituents of A. vera have shown biological response modifying activities 
especially acemannan and alprogen. Acemannan (acetylated β1-4 linked glucomannan), a 
major component of its gel (Femenia et al., 1999; Gowda, 1979) showed both 
immunoregulatory and immunostimulatory effects including stimulation of humoral arm, 
increased phagocytosis and oxidative effects (Rajasekaran et al., 2005; Altug et al., 2010). 
Acemannan is a medium sized polysaccharide of molecular weight (200,000-1,000,000) 
(Zhang and Tizard, 1996; Liu et al., 2006; Zhang et al., 2006), maximum BRM activities 
have shown between 5 kDa to 400 kDa (Im et al., 2005). Acemannan (800mg/day) has 
significantly increased macrophages and circulating monocytes; and showed clinical 
improvements in acquired immunodeficiency syndrome patients (McDaniel et al., 1990). 
Acemannan also found effective against spontaneously evolved feline and canine 
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fibrosarcomas (King et al., 1995). Acemannan associated macrophage activation led to an 
increased phagocytosis and release of inflammatory cytokines including interleukin-6 and 
tumour necrosis factor (Zhang and Tizard, 1996), increased nitric oxide production (Karaca 
et al., 1995; Djeraba and Quere, 2000), hematopoiesis and induced immature dendritic cell 
proliferation (Lee et al., 2001). Moreover, stimulation of human lymphocytes antigenic 
response and all types leucocytes formation from bone marrow and spleen have also been 
documented (Singh et al., 2011). Alprogen, another BRM of A. vera origin, possesses 
inhibitory effect on the release of leukotriene, histamine and calcium influx from mast cells 
(Ro et al., 2000). A. vera glycoproteins (lectins) have also shown BRM activities and act as 
carrier proteins and activate T cells (Harlev et al., 2012).These activities occur by modulation 
of DNA damage activated signal transduction pathways. A. vera polysaccharides effect on 
cytokine cascade and antigen presenting cells (Strickland, 2001; Singh et al., 2011). 
 Several investigators reported that its gel components including acetylated mannan, 
glucomannan and galactogalacturan, significantly reduced tumor cells upon intraperitoneal 
administration in mice (Peng et al., 1991; Yagi et al., 1997). Acetylated mannan stimulated 
an increase in splenic cellularity, white blood cells, lymphocytes, monocytes and neutrophils 
in mice (Davis et al., 1989; Egger et al., 1996). A. vera potentiated both humoral and cell 
mediated immunity in mice, at the dose of 100mg/kg and suppressed delayed type 
hypersensitivity. The researchers suggested A. vera as an immunotherapeutic agent in 
immunologic diseases (Chandu et al., 2011). These immune regulatory activities have been 
shown due to presence of polysaccharides and glycoproteins (Dua et al., 1989). 
Polysaccharides have anticomplement activity (Hart et al., 1989). Its proteins and enzymes 
act as chemotactic agent, increase white blood motility (leucocytes) into stressed area (Fijita 
and Teradaira, 1976; Heggers and Robson, 1985; Reynolds and Dweck, 1999). A. vera 
carbohydrates showed hematopoietic activities (Talmadge et al., 2004). In another study, 
immunomodulation of its gel was assessed in mice (at dose rate of 150mg/kg and 300mg/kg 
body weight) for five days and total white blood cells count, antibody production, plaque 
forming cells and peritoneal macrophages phagocytic activity were assessed. Gel 
administration at the dose rate of 300 mg/kg showed significant increase in white blood cells 
(WBC) count, higher antibody titers, higher number of plaque forming cells and an increased 
phagocytic activity of peritoneal macrophages than control. It stimulated proliferation of 
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stem cells and humoral immunity, which is indicated by increased total white blood cell 
counts, plaque forming cells and circulating antibodies (Halder et al., 2012). Madan et al. 
(2008) suggested A. vera use as immunomodulator in immunosuppressed clinical diseases. 
Its polysaccharides are plant origin immunopotentiator (Sun et al., 2011) and activate T cell 
mediated immunity (Strickland, 2001), however immune regulation pathways are not 
completely understood (Kim et al., 1998). Beta-glucan polysaccharide in it acts as non-
specific immunopotentiating biologic response modifier (Pelley and Strickland, 2000). Beta-
glucan and acemannan stimulate macrophage by binding mannose receptors (Weis et al., 
1998). Orally taken polysaccharides are partially hydrolyzed by intestinal bacteria into 
fragments. Further they can bind gut epithelium and show localized effects on immune 
system. They can also be absorbed in blood stream and show systemic effects (Ramberg et 
al., 2010). 
 Kwon and his coworkers (2011) investigated levels of Th1, Th2, IL-2, IL-4, IL-10, 
IgA and IFN-γ in mice. A. vera medicated groups produced significantly high concentration 
of IL-4, IL-10 and IgA. However, IFN-γ and IL-2 concentration showed non-significant 
response. IgA represented as an important mucosal surface antibody. IL-4 (cytokine) showed 
very important effects in humoral immunity through precursor T cells differentiation to Th2 
helper cells. It also increased IgG1 production from B-lymphocytes (Nicola, 1994). Increased 
IL-4 concentration produced more antibodies in medicated groups. IL-10 (an anti-
inflammatory cytokine produced by Th2 cells) antagonized Th1 and inhibited IL-2, IL-6, and 
IFN-γ production from macrophages (Florquin et al., 1994); whereas, Th1cytokines (TNF-α, 
IFN- γ, IL-1, IL-2, and IL-6) involved in septic shock (Bayston and Cohen, 1990; Rongione 
et al., 1997). Cytokines act as biological response modifiers by modulation of immune 
responses, haematopoiesis and inflammation in innate and adaptive immunity. Consequently, 
induced cytokines were balanced by A. vera peel extract. Its active anthraquinones (aloin and 
emodin) components showed immunomodulatory effects (Pandey, 2010) by reducing 
Th1cytokines and promoting Th2 (Liu et al., 2009). A. vera peel medication also showed 
elevated levels of IgG and IgA (Kwon et al., 2011). 
 A. vera administration has showed marked increase in proliferative and phagocytic 
activity of reticuloendothelial system (Im et al., 2005). It stimulated humoral and cell 
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mediated immunity by stimulating cells forming erythroid and myeloid colonies, granulocyte 
macrophage colony-forming cells and murine pluripotent hematopoietic stem cells (Egger et 
al., 1996; Boudreau and Beland, 2006). Various scientists reported that these 
immunomodulatory effects were due to innate immune cells activation (NK cells, 
macrophages, lymphocytes and neutrophils), production and release of cytokines (IL-1, IL-2, 
IL-6, IL-8, IFN-γ and TNF-α), increased nitric oxide production and induced antibodies 
production (Yates et al., 1992; Pugh et al., 2001; Brown and Gordon, 2003; Boudreau and 
Beland, 2006). 
 Vahedi et al. (2011) investigated effects of A. vera extract on cellular and humoral 
immune responses in rabbits. Results showed a significant increase in CD4+(after 14 and 21 
days) and CD8+lymphocytes (after 7, 14 and 21 days) in administered groups as compared to 
control. CD4+ (white blood cells) have essential role in combating against infections. Its 
count in blood indicated functioning of immune system (Shirwan et al., 2003). These 
CD8+cells (transmembrane glycoprotein), function as co receptor of T cell receptors. They 
bind to major histocompatibility complex class 1 present on natural killer cells and cytotoxic 
T cells (Vecchione et al., 2002). Various researchers showed that A. vera administration 
enhanced IgG, CD4+ and CD8+concentrations. Therefore, immune enhancing action might be 
due to increased synthesis and release of cytokines (IL-1, IL-2, IL-6, IL-8, IFN-γ and TNF-α) 
and production of specific and nonspecific antibodies (Hanaue et al., 1989; Qiu et al., 2000; 
Sampedro et al., 2004; Leung et al., 2004). CD8+cells have a significant role in cellular 
immune responses and CD4+ cells take part in humoral and cellular immune responses. CD4+ 
according to their function (cytokines release) divided into two types of cells, Th1 and Th2. 
Th1 stimulated cells activate macrophages and induce T cell cytotoxicity by release of 
cytokines (TNF-β, IL-2, and IFN-γ). These stimulated Th2 cells produce B cells, stimulate 
cytokines (IL-4, IL-5, IL-10 and IL-13), which further increased B cells production (Chinnah 
et al., 1992). 
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 Altug et al. (2010) investigated A. vera and β-Glucan effects on immune system in 
polyvalent vaccinated dogs. Their findings match with previous researchers as A. vera  
medication stimulated cellular and humoral immune responses, increased platelets count and 
restored thrombocytopenia. 
 The effects of ethanolic and aqueous extracts of A. vera on immune functions of 
broiler birds with induced coccidiosis has been investigated in our laboratory. Results of 
study showed a significantly higher lymphoproliferative response in chickens administered 
with ethanolic extracts. Birds showed 60 % protection against coccidiosis challenge. It was 
concluded that A. vera may have a potential to stimulate immune responses and can be 
successfully used as immunotherapeutic agent against coccidiosis in industrial broiler 
chickens (Akhtar et al., 2012). 
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3.1. Procurement and processing of Aloe vera 
Aloe (A.) vera (Aloe barbadensis Miller) used in the present study were procured 
from Botanical garden, University of Agriculture, Faisalabad (UAF), Pakistan and got 
authenticated by a botanist in the Department of Botany, UAF, Pakistan. The plant specimens 
were kept in the Ethno-veterinary Research and Development Centre, Department of 
Parasitology, UAF as voucher No. 0173.  Immediately after harvesting, leaves were washed 
with water containing chlorine (5-10 parts per million; ppm) and then with a solution 
containing formalin (37 % formaldehyde; 0.001-0.005 ppm) and finally with distilled water 
(Femenia et al., 1999). 
3.1.1. Preparation of Aloe vera leaf gel  
Mucilaginous leaf gel was collected from the cleaned A. vera leaves within three to 
four hours post-harvesting to minimize any deterioration. For this purpose, one leaf was 
taken at a time, placed its flat side on a cutting wooden board and epidermis was removed by 
using sharp knife. Afterwards, serrated edges of both sides of the leaf were cut off to make 
slices of the leaf lengthwise. With the help of a wooden spatula, gel was scrapped out, 
thoroughly homogenized followed by filtration through cheese cloth and stored in screw 
capped glass bottles at 4°C in a refrigerator for further use. 
3.2. Isolation and Characterization of Aloe vera biomolecules  
3.2.1. Polysaccharides Extraction 
Polysaccharides from the A. vera gel were extracted according to the method 
described by Chang et al. (2011). Briefly, A. vera gel, was vigorously mixed with four 
volume of 95% (v/v) ethanol and kept overnight at 4 °C. The precipitate thus obtained was 
centrifuged at 6500 g for 10 minutes and supernatant was discarded. The precipitate 
dissolved in double distilled water and kept overnight. It was again precipitated with four 
volume of 95% (v/v) ethanol. The precipitation and solubilization procedures were conducted 
repeatedly to remove all the colored materials. Finally, the precipitate thus obtained was 
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mixed in doubled distilled water and treated with Sevag reagent {1:4 (v/v) (1-butanol: 4-
chloroform)}. Free proteins were removed by repeated oscillation and centrifugation (Staub, 
1965). This solution was mixed with three volumes of ethanol (95%, v/v) which precipitated 
polysaccharides. The crude polysaccharides thus obtained were further purified by washing 
twice with absolute ethanol followed by acetone and ethyl-ether. Then, it was dried 
completely at 40°C for 48 hours (Chang et al., 2011). 
3.2.2 Characterization  
3.2.2.a. Hydrolysis 
The polysaccharides were hydrolysed to get the monosaccharides according to the 
procedure described by Osborn et al. (1999) with minor modifications. Briefly, the 
polysaccharides were reﬂuxed in 2M Trifloroacetic acid (TFA) (Sigma-Aldrich®, USA) at 
100°C for 2 hours in a round-bottomed ﬂask equipped with a reﬂux condenser. The TFA was 
then removed by evaporation at 75°C and the water was removed by freeze drying (-65 °C) 
overnight. 
3.2.2.b. High Performance Liquid chromatography (HPLC) analysis for determination of 
monosaccharides  
 The monosaccharides were analysed on a Shimadzu-10A HPLC workstation (Japan) 
supplied with a quaternary gradient pump unit and a refractive index detector (RID). The 
analytical columns to get absorption spectra included Rezex RCM-Monosaccharide Ca+2 and 
Phenomenex (80°C temperature and a wavelength of 235 nm). Isocratic double distilled 
water (DD H2O) was used as mobile phase. For analysis 20μl injection volume was taken for 
every sample and standards. 
3.3. Aloe vera proteins extraction  
Proteins from A. vera gel were extracted according to the method adopted by He and 
Wang (2008) with minor modifications. Briefly, A. vera leaves were ground with liquid 
nitrogen. The powdered leaf tissue (0.2 g) was washed with acetone (1mL) containing 0.2% 
dithiothreitol. Then it was vortexed for 1 minute in an eppendorf tube and centrifuged at 
15,000 g for 20 minutes at 4°C followed by drying on ice. Powdered tissue (2 g) was 
homogenized in 2 ml of 2X extraction buffer (20mM Tris-HCl; pH 7.5, 250 mM sucrose, 10 
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mM ethylene glycol tetraacetic acid, 1mM phenylmethylsulfonyl fluoride, 1% Triton X-100 
and 2% β-mercaptoethanol). The proteins thus precipitated were dissolved in lysis buffer (7 
M urea, 2 M thiourea, 4% CHAPS (3-[(3 Cholamidopropyl) dimethylammonio]-1-
propanesulfonate), 2% ampholine (pH 3–10) and 1% dithiothreitol). Protein concentration 
was measured by Bradford method (Bradford, 1976).  
3.3.1.a. Quantification of protein  
 The method involves the binding of Coomassie Brilliant Blue G-250 to protein. This 
dye binding caused changes in absorption from 465-595 nm, and increased in absorption at 
595 nm was monitored by spectrophotometer. 
Coomassie Brilliant Blue G-250 (Sigma) 100mg was dissolved in 50 mL of 95% ethanol. To 
this solution 100 mL 85% (w/v) phosphoric acid was added. The resulting solution was 
diluted to final volume of one liter. Final concentrations in the reagent were 0.01% (w/v) 
Coomassie Brilliant Blue G-250, 4.7% (w/v) ethanol, and 8.5% (w/v) phosphoric acid. 
3.3.1.b.  Protein assay (standard method) 
 Protein solution containing 10 to100µg protein in a volume up to 0.1 mL was 
pipetted into 12 x 100 mm test tubes. The volume in the test tube was adjusted to 0.1 mL 
with appropriate buffer. Five milliliters of protein reagent was added to the test tube and the 
contents mixed either by inversion. The absorbance at 595 nm was measured after 2 minutes 
and before 1 hour in 3 ml cuvettes against a reagent blank prepared from 0.1 mL of the 
appropriate buffer and 5 mL of protein reagent. The weight of protein was plotted against the 
corresponding absorbance resulting in a standard curve used to determine the protein in 
unknown samples. 
3.3.1.c. Microprotein assay 
 Protein solution (extracted from A. vera) containing 1- 10 µg protein in a volume up 
to 0.1 ml was pipetted into 12 x 100 mm test tubes. The volume in the test tubes was adjusted 
to 0.1 mL with the appropriate buffer. One milliliter of protein reagent was added to the test 
tube and the contents mixed as in the standard method. Absorbance at 595 nm was measured 
as in the standard method except in 1 mL cuvettes against a reagent blank prepared from 0.1 
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mL of the appropriate buffer and 1 mL of protein reagent. Standard curves were prepared and 
used as in the standard method. 
3.3.2. Characterization of proteins  
  Proteins isolated from A. vera leaves were subjected to automated electrophoresis 
system (BioRad®, USA) for their quantification and determination of molecular masses 
according to the instructions of the manufacturer. 
3.4. Infective material for challenge experiment 
3.4.1. Collection and processing of chicken guts 
Chicken guts suspected to be naturally infected with Eimeria species were collected 
from different commercial poultry sale points and outbreak cases of poultry farms of 
Faisalabad district. All the collected guts were brought and investigated in the 
Immunoparasitology Laboratory, Department of Parasitology, University of Agriculture, 
Faisalabad, Pakistan. Guts were opened by giving longitudinal incision and contents were 
examined by direct microscopy (Soulsby, 1982). The contents from the positive guts were 
placed in 2.5% sodium hypochlorite (Speer et al., 1973). The suspension was diluted twice 
with distilled water (4:1) to remove sodium hypochlorite and the sediment thus obtained was 
subjected to sporulation process. 
3.4.2. Sporulation and purification of oocysts 
The contents from the positive samples were subjected to sporulation in 2.5% 
potassium dichromate (K2Cr2O7) solution (upto 6 mm thickness) in petri dishes. The 
sporulation was confirmed by microscopic examination after an interval of every 12 hours. 
After the completion of sporulation, suspension was thoroughly mixed with the help of a 
glass rod and passed through a muslin cloth followed by filtration through a sieve. The 
filtrate was centrifuged at 1500g for 10 minutes and sediment thus obtained was subjected to 
Zinc Sulphate (ZnSO4) Floatation technique following the method of Levine (1961). Briefly, 
ZnSO4 floatation solution (Annexure I) was mixed with equal quantity of the suspension of 
sporulated oocysts and centrifuged (1500 g for 10 minutes). The supernatant having 
sufficient number of sporulated oocysts was aspirated by using the pippeting system and 
collected in a separate jar. The sediment was processed in the same way until no sporulated 
25 
  
oocysts remained in the supernatant. Sporulated oocysts were washed thrice with phosphate 
buffered saline (PBS; pH 7.2), placed in a sterilized screw capped bottle and stored at 4°C till 
further use. 
Sporulated oocysts, mixed species of genus Eimeria, were identified on the basis of 
their predilection site, morphology and size according to Reid and Long (1979) (Annexure 
II). 
3.4.3. Quantification of Sporulated oocysts 
Purified suspension of sporulated oocysts (mixed species; local isolates) was 
subjected to McMaster counting technique to quantify the number of sporulated oocysts per 
mL of suspension and to adjust the infective dose (Ryley et al., 1976). The final 
concentration was adjusted to 6.5×104-7.0×104 sporulated oocysts per 2mL of PBS.  
3.5. Experimental design  
The whole study was divided into two experiments viz. Experiment I and II. 
Experiment-I was meant for the evaluation of polysaccharides from A. vera gel for their 
biological response modifier (BRM) and immunotherapeutic activities; whereas, Experiment-
II was conducted to evaluate the BRM and immunotherapeutic activities of proteins isolated 
from A. vera leaves. 
3.5.1. Experiment-I 
A total of 320 day old industrial broiler chicks (Hubbard) purchased from local 
hatchery were reared in coccidia-free environment at Experimental Station, Department of 
Parasitology, University of Agriculture, Faisalabad, Pakistan. All the chicks were fed 
withdrawal feed and water ad libitum. After 5 days of acclimatization, chicks were randomly 
divided into four main treatment groups namely A1, A2 and A3 each containing 80 chicks; 
whereas, A4 served as control group. Each treatment group was further divided into two sub-
groups each containing 40 chicks and were administered orally with the following treatments 
by using oral gavages for three consecutive days i.e. day 5th, 6th and 7th of age as per 
schedule. 
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Groups Treatment Dose/ Kg of body weight/day 
A1 Polysaccharides from A. vera gel 
(Each conc. dissolved in 3 mL PBS) 
100 mg 
A2 200mg 
A3   300 mg 
A4 Control group (PBS) 3 mL 
3.5.2. Experiment-II 
For experiment-II, 320 day old industrial broiler chicks procured from local hatchery 
were reared in the same conditions like that of Experiment-I at Experimental Station, 
Department of Parasitology, University of Agriculture, Faisalabad, Pakistan. After 5 days of 
acclimatization, chicks were randomly divided into four main treatment groups namely B1, 
B2, and B3 containing 80 chicks. The group B4 served as control group. Each treatment group 
was further sub-divided into two sub-groups each containing 40 chicks and were 
administered orally with the following treatments by using oral gavages for three consecutive 
days i.e. day 5th, 6th and 7th of age as per schedule. 
Groups Treatment Dose /Kg of body weight/day 
B1 Proteins from A. vera leaves 
(Each conc. dissolved in 3 mL PBS) 
100 mg 
B2 200 mg 
B3 300 mg 
B4 Control group (PBS) 3mL 
In both the experiments, chickens in all the groups were routinely vaccinated 
according to the routine schedule (Annexure III) (Awais, 2010). 
On day 14th post-administration of A. vera bio-molecules, half of the chickens from 
each group were used for immunological evaluation and the remaining half for therapeutic 
evaluation 
3.6. Immunological evaluation 
The effect of A. vera bio-molecules on the cellular and humoral immune responses 
were investigated. Cell mediated immune response was evaluated by in vivo and in vitro 
lymphoproliferative responses to Phytohemagglutinin-P (PHA-P), Carbon particle clearance 
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assay and Concanavalin-A (Con-A), respectively; whereas, antibody responses to sheep red 
blood cells (SRBCs) were used to detect the humoral immune responses. 
3.6.1. Cell mediated Immune responses 
3.6.1.a. In vivo lymphoproliferative response to PHA-P 
Classic toe-web assay was used to quantify the in vivo lymphoblastogenic response to 
PHA-P as described by Corrier (1990). 
Test Procedure 
i. On day 14th post-administration of A. vera  bio-molecules, experimental and control 
chickens were injected PHA-P (Sigma®, USA) intradermally (100µg/100µL/chicken) 
between the third and fourth digits of the right foot.  
ii. The left foot was injected with PBS (100µL) to serve as control.  
iii. The thickness of the inter-digital skin was measured at 24, 48 and 72 hours post injection 
with the help of a pressure sensitive micrometer screw gauge. 
iv. Lymphoproliferative response to PHA-P was calculated by using the formula. 
Lymphoproliferative response = (PHA-P response, right foot) – (PBS response, left foot) 
3.6.1.b. In vitro lymphoproliferative response to Concanavalin-A (Con-A) 
Peripheral blood lymphocytes blastogenesis assay was used to evaluate the in vitro 
lymphoproliferative response in both treated and untreated chickens according to the method 
described by Qureshi et al. (2000). 
Procedure 
i. On day 7th and 14th post administration of A. vera bio-molecules, birds from each 
experimental and control groups were randomly assigned for in vitro 
lymphoblastogenesis assay. 
ii. Chickens were killed humanely and blood samples (5mL/chicken) were collected by 
heart puncture with a heparinized syringe and diluted with equal volume of PBS. 
iii. The peripheral blood lymphocytes (PBLs) were separated by layering the heparinized 
blood on Histopaque-1077 (Sigma®, USA) followed by centrifugation at 400g for 30 
minutes at room temperature (26°C).  
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iv. Mononuclear cells migrate during centrifugation, forming a distinct, opaque layer at 
the plasma- Histopaque-1077 interface.  Plasma phase (top layer) was removed 
carefully and lymphocytes layer was collected by aspiration. 
v. The cells were washed thrice with PBS and adjusted to a concentration of 3x106/mL 
of RPMI-1640 growth medium (Sigma-Aldrich®, USA), supplemented with fetal calf 
serum (Sigma-Aldrich®, USA) (7%) inactivated at 56 °C and 1μg/mL gentamicin. 
vi. PBLs (100µL suspension), containing 0.3x106 cells from each group were added to 
five wells (in duplicate) of a flat bottomed microtitration plate (96-wells; Medium 
binding, polystyrene, Flow Labs., UK) followed by the addition of Con-A (Sigma®, 
USA) (25 µg/100µL) to five wells; whereas, other five wells served as unstimulated 
controls.  
vii. The plates were incubated at 41°C in an incubator in the presence of 5% CO2 and 50-
70% humidity.  
viii. After 22-24 hours of incubation, 50µL of a 0.1mg/mL stock of MTT (3-[5,5-
dimethylthiazol-2-yl]-2,5-[diphenyltetrazolium]) (Sigma®, USA) was added to each 
well and the plates were re-incubated for another 4 hours.  
ix. After that, liquid from all the wells was carefully removed and 150 µL of MTT acid 
(200 mL 2-propanol [isopropyl alcohol] + 1.32 mL conc. HCl + 100 mL PBS) was 
added to each well and Trypan blue crystals (Merck®, Germany) were dissolved by 
repeated pipetting.  
x. The optical density (OD) was read on a plate reader (BioTek-MQX200, USA) at 540 
nm wavelength.  
xi. The mean OD values from each group were used to calculate the stimulation indices 
by using the formula: 
Mean OD value = Con A stimulated – unstimulated 
                                   unstimulated 
3.6.1.c. Carbon particle clearance assay 
 The phagocytic ability of chickens blood cells was determined by carbon particle 
clearance assay. On day 14th post administration of A. vera polysaccharides (experiment I) 
and proteins (experiment II) carbon particle clearance assay was performed as described by 
Zhang (2007). Briefly, India ink was centrifuged to get supernatant. A 0.05ml/10g/body 
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weight, India ink was injected into wing vein of chickens and blood was collected from other 
wing vein at 3 and 15 minutes post injection of India ink. The blood samples were placed in 
tubes containing 2ml of 0.1 % sodium carbonate and optical density values were measured at 
600nm in a spectrophotometer.  
 The clearance index (K), phagocytic index (α) and immune organ index (organ-body 
weight ratios) were calculated by following formulas (Hou et al., 2010). 
K = (logOD3–logOD7) 
       t2-t1 
 
α  =    ______Body weight__________ 
           (spleen weight+liver weight)  3√K 
 
Immune organ index= immune organ weight (mg) 
                                 Body weight (g) 
 
3.7. Humoral Immune responses 
3.7.1. Antibody response to sheep red blood cells (SRBCs) 
Sheep red blood cells were used as T-dependent antigens to demonstrate the antibody 
response.  
Preparation of SRBCs  
i. Blood sample (5mL) was collected from a healthy sheep maintained by the Institute 
of Microbiology, University of Agriculture, Faisalabad, Pakistan, through jugular 
vein in a sterile tube containing anti-coagulant EDTA (10mg EDTA/5mL of blood). 
ii. Blood collected was centrifuged at 1500g for 15 minutes, plasma and buffy coat 
layers were decanted and pelleted RBCs were washed thrice with PBS. 
iii. The concentration of washed RBCs was adjusted to 5% (v/v) with PBS. 
Haemagglutination Test 
Anti-SRBC antibody titers were detected by using microplate haemagglutination test 
according to the method of Yamamoto and Glick (1982) with minor modifications suggested 
by Qureshi and Havenstein (1994). 
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On day 14th post administration of A. vera bio-molecules, 10 chickens from each 
experimental and control groups were injected with 1 mL of 5% saline suspension of SRBCs 
via intramuscular route. At day 14th post-first injection, a booster injection of SRBCs (1 mL) 
was injected in 5 chickens out of the ten chickens initially injected with a primary injection 
of SRBCs. Blood samples from all the chickens were collected on 7th and 14th days post 
primary and booster injections to separate the sera samples that were used to detect the anti-
SRBC antibody titers by haemagglutination test, carried out in 96 well round bottom 
microtitration plates (Flow Labs., UK).  
Test Procedure 
i. PBS (50 µl) was added in all the wells of a round bottom microtitration plate (Flow 
Labs., UK). 
ii. Test sera (50 µl) was added in first well and after proper mixing 50 µl sample was taken 
out from 1st well and transferred to the next one and so on up to the 11th well to make the 
two fold serial dilutions as 1:2, 1:4, 1:8,…………1:2048; whereas, last well was kept as 
negative control. 
iii. Suspension of 5% (v/v) SRBCs (50 µl) was added in each well of the microtitration plate 
and mixed gently. 
iv. The plates were incubated at room temperature (26 °C) for half an hour and results were 
recorded. 
v. The titer of the well containing 50% agglutination and 50% reticulum settling (clumping) 
was considered as the total anti-SRBC antibody titer of the test sera. 
vi. Same protocol was adopted for IgG titers except in the first step 50 µl of 0.01M 2-
mercaptoethanol (2-ME) (Riedel-de Haen, Germany) was added in PBS in each well that 
destroyed the IgM immunoglobulins and the remaining titer was of IgG. 
vii. IgM titer was calculated by subtracting the IgG titer from total antibody titer of the 
respective samples. 
viii. Results were expressed in terms of Geo-mean titer (GMT) (Burgh, 1978). 
3.8. Relative weight of lymphoid organs 
Chickens from all the experimental and control groups were individually weighed for 
live weight and sacrificed at day 21st (fourteen days post administration of A. vera bio-
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molecules). Lymphoid organs including bursa of fabricius, thymus, spleen and caecal tonsils 
were incised out and weighed. Per cent organ weight ratio relative to the live body weight 
(immune organ index) was calculated by using the formula as described by Giambrone and 
Closser (1990): 
 
Organ-body weight ratio    = 
 
     Organ weight (gm)         × 100 
   Live body weight gain (gm) 
3.9. Feed conversion ratios (FCR) 
Chickens from all the groups were weighed on weekly basis post administration of A. 
vera extracts. Feed given to each group was also recorded on weekly basis and the data thus 
obtained was used to calculate the weekly FCR by using the formula as described by Singh 
and Panda (1992): 
Feed conversion ratio = 
Feed consumption (gm) 
Body weight gain (gm) 
3.10. Therapeutic evaluation 
Forty chickens from each group were challenged with 6.5×104-7×104 sporulated 
oocysts of mixed species of genus Eimeria (local isolates mainly, E. tenella, E. acervulina, E. 
maxima and E. necatrix) on day 14th post administration of A. vera bio-molecules. Chickens 
of each group were monitored for body weight gains per day from day 3rd to 12th post 
challenge. Droppings from each group were collected and examined on alternate day from 
day 4th to 12th post challenge to determine the oocysts per gram of droppings by McMaster 
counting technique (Ryley et al., 1976).  
During challenge experiment, chickens of each group were monitored for mortality. 
Dead and survived chickens in all the groups were sacrificed and scored for lesion scoring 
(Johnson and Reid, 1970).  
Further, the per cent protection against lesions was calculated by using the formula 
described by Singh and Gill (1975): 
 
Per cent Protection against lesions =   Average lesion score (IUC) – Average lesion score (IMC) ×100 
      Average lesion score (IUC) 
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3.11. Anticoccidial index (ACI) 
Anticoccidial index was calculated by using formula as described by Shah et al. 
(2009):  
ACI= (relative rate of weight gain + survival rate)-(lesion value + oocyst value) 
Relative rate of weight gain was calculated by subtracting weight gain at the time of 
challenge from the body weight at the end of experiment. Survival rate was estimated by the 
number of surviving chickens divided by the initial number of chickens. 
Lesion score of the chickens from all groups were calculated by method of Johnson and Reid 
(1970); and oocyst value was calculated by using the formula described by Peek and 
Landman (2003) as (the number of oocysts from the positive control chickens-Treated 
chickens)/positive control chickens x 100%). 
3.12. Effect on the development of lymphoid organs of chickens 
Chickens from each group were individually weighed and slaughtered on day 12th 
post challenge. Lymphoid organs including bursa of fabricius, thymus, spleen and caecal 
tonsils were removed surgically and weighed to demonstrate the correlation of disease with 
their development, if any, in experimental and control chickens. The data thus collected was 
expressed as per cent organ-body weights ratio relative to the live body weight by using the 
formula as described earlier. 
3.13. Statistical analysis  
One way analysis of variance (ANOVA) and Duncan’s multiple range (DMR) tests 
were used for the determination of statistical significance using statistical analysis software 
(SAS®, 2004). Data on per cent mortality and protection were analyzed using the Chi square 
test. Differences were considered statistically significant at p<0.05. 
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CHAPTER 4  
                                                                             RESULTS 
 
 In the present study, Aloe (A.) vera polysaccharides and proteins were isolated and 
characterized; and evaluated as biological response modifiers and therapeutic agents against 
coccidiosis in chickens. 
Experiment-I 
4.1. Isolation and characterization of Aloe vera polysaccharides  
4.1.1. High Performance Liquid Chromatography (HPLC) analysis  
A. vera monosaccharides quantitative HPLC analysis resulted in three distinct peaks 
on chromatogram at different retention time. These peaks were compared with standards, 
which showed three different monosaccharides including maltose, glucose and mannose in 
hydrolyzed solution of A. vera at retention times 9.423, 11.080 and 12.55, respectively. 
Molar concentration percentage quantities of these detected monosaccharides in hydrolyzed 
solution of A. vera polysaccharides are presented in Table 4 A. 
4.1.2. Immunological evaluation 
For immunological evaluation, both cell mediated and humoral immune responses 
were detected. Cell mediated immune responses were detected by in vivo lymphoproliferative 
response to PHA-P and carbon particle clearance assay. In vitro cell mediated immune 
responses were detected by lymphoproliferative response to Concanavalin-A (Con-A). 
Humoral immune responses were demonstrated by antibody response to sheep red blood 
cells. 
4.1.2a. Cell mediated immune (CMI) responses 
i. In vivo lymphoproliferative response (mm) to Phytohaemagglutinin-P (PHA-P) 
To demonstrate in vivo CMI response, lymphoproliferative response to PHA-P was 
calculated. For this purpose, the amplitude of toe-web swelling was measured at 24, 48 and 
72 hours after PHA-P injection in all experimental and control groups. A. vera 
polysaccharides administered groups showed significantly higher (p<0.05) 
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lymphoproliferative response in all experimental groups as compared to control. Maximum 
swelling was observed at 24 hours post PHA-P injection in all groups followed by 48 and 72 
hours. Maximum swelling after 24 hrs (1.13±0.11) was noticed in group A2, which was 
administered with A. vera polysaccharides at the dose rate of 200mg/kg body weight. Results 
of group A2 were followed by A3 (1.09±0.15), A1 (1.00±0.12) and A4 (0.68±0.03). The 
difference was statistically non significant (p>0.05) between experimental groups A3 and A1 
administered with A. vera polysaccharides at the dose rate of 300 and 100 mg/kg body 
weight, respectively. At 48 hours post administration of A. vera polysaccharides, group A2 
showed significantly higher response (0.92±0.02) followed by group A3 (0.89±0.02), A1 
(0.76±0.04) and A4 (0.62±0.01). Group A3 showed statistically similar response to group A1 
and A2. At 72 hours group A2 (0.81±0.07) showed significantly higher response (p<0.05) as 
compared to all groups including A3 (0.78±0.05), A1 (0.61±0.03) and A4 (0.40±0.03), 
respectively. On the whole, groups A2 and A3 showed higher responses to PHA-P as 
compared to A1 and A4 (control) groups (Table 4.1; Figure 4.1). 
ii. In vitro lymphoproliferative response to Concanavalin-A (Con-A)   
In vitro lymphoproliferative response to concanavalin-A was detected at 7th and 14th 
day post administration of A. vera polysaccharides at graded doses in all groups by 
lymphoblastogenic response of chickens peripheral blood  lymphocytes (PBLs) to Con-A. 
All the experimental groups showed significantly higher (p<0.05) response in the PBLs of 
chickens as compared to those of control group, both on day 7th and 14th post administration 
of A. vera polysaccharides. However, among the treatment groups, chickens administered 
with A. vera polysaccharides at the dose rate of 200 and 300 mg/kg of body weight showed 
significantly higher (p<0.05) response as compared to those administered with A. vera 
polysaccharides at dose rate of 100 mg/kg of body weight (Table 4.2; Figure 4.2). 
iii. Carbon particle clearance assay 
On 14th day post administration of A. vera polysaccharides, carbon particle clearance 
assay was performed to check the phagocytic activity of chicken macrophages. The clearance 
index (K), phagocytic index (α) and immune organ index were calculated at 3 and 15 minutes 
post injection of India ink. 
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The results of clearance index showed significantly higher (p<0.05) clearance index 
in control group A4 (0.0185±0.0040) and other experimental groups showed low clearance 
index values indicating less carbon in blood. Among the experimental groups, group A2 
showed lowest K value (0.0073±0.0024) followed by group A1 (0.0106±0.0039) and A3 
(0.0124±0.0019). A3 response was statistically similar to group A1 and A4 (Table 4.3; Figure 
4.3 a) 
The results of phagocytic index (α) showed significantly higher (p<0.05) response in 
all three experimental groups as compared to control. Maximum response was observed in 
group A2 (94.8283±9.3211), which was administered with A. vera polysaccharides at the 
dose rate of 200mg/kg body weight, followed by A1 (69.3054±13.6106) and A3 
(51.2677±10.2013). Statistically, group A2 showed significantly higher (p<0.05) phagocytic 
index followed by group A1; whereas, A3 showed response, which was similar to group A1 
and A4 (Table 4.3; Figure 4.3 b). 
4.1.2b. Humoral Immune responses 
i. Antibody response to sheep red blood cells (SRBCs) 
Humoral immune responses were detected by performing haemagglutination test in 
chickens of experimental and control groups on day 7th and 14th post primary and secondary 
injections of SRBCs; and serum antibody response to sheep RBCs were calculated as total 
immunoglobulins Igs, IgM and IgG titers. The results were explained in terms of geomean 
titers (GMT) (Table 4.4; Fig.4.4 a-d).  
In the present study, all the experimental groups showed higher Igs, IgM and IgG 
titers as compared to control. However, at day 7th post primary injection (PPI), 
polysaccharides administered group A2 (at the dose rate of 200mg/kg body weight) showed 
maximum Igs, IgM and IgG titers (73.52, 52.4, 21.11) followed by group A3 (64, 48, 16) 
group A1 (42.22, 28.29, 13.92) and A4 (32, 19.87, 12.12). On day 14th PPI, geomean titer for 
total anti-SRBC antibodies was highest in group A2 (55.72, 18.95, 36.75) followed by A3 
(42.22, 14.36, 27.85), A1 (42.22, 17.97, 24.25) and A4 group (24.25, 8.25, 16). A similar 
trend was observed on day 7th and 14th post-secondary injections (PSI). 
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4.1.3. Effect on the development of lymphoid organs of chickens 
The organ-body weight ratio (immune organ index) of lymphoid organs was 
calculated on day 14th post administration of A. vera polysaccharides including bursa of 
fabricius, spleen, thymus and caecal tonsils. Experimental groups showed apparently higher 
per cent organ-body weight ratios as compared to control group; whereas, the statistical 
difference was non-significant (p>0.05) in immune organs of all groups except thymus of 
experimental group A2 showed statistically significant response as compared to control 
(Table 4.5; Figure 4.5). 
4.1.4. Effects of polysaccharides on weight gains and feed conversion ratio (FCR) 
Weekly weights and feed consumed were monitored as indicator of performance in 
all the groups and results expressed in terms of weekly weight gains and weekly FCR from 
1st to 6th week. Experimental groups (A2 and A3) showed significantly higher (p<0.05) weight 
gains as compared to group A1 and A4, control. Maximum weight gains (gm±SE) were 
observed at 6th week in group of chickens administered with A. vera polysaccharides. Among 
the experimental groups, maximum weight gains were observed in group A3 (1753.33±174.7) 
followed by A2 (1683.33±104.0), A1 (1566.67±28.87) and control group A4 (1500.00±152.7) 
(Table 4.6; Figure 4.6).  
Similarly, all experimental groups administered A. vera polysaccharides showed 
better FCR as compared to control. However, FCR was better in group A3 (1.95) followed by 
group A2 (1.96), A1 (2.01) and control group A4 (2.16) (Table 4.7; Figure 4.7). 
4.1.5. Challenge experiment 
a. Oocyst Count 
Experimental and control groups administered with mixed Eimeria species (6.5×104-
7.0×104 sporulated oocysts) were monitored for oocysts per gram (OPG) of droppings from 
day 4th to 12th post challenge. All the experimental groups showed significantly lower OPG 
than control (p<0.05) and maximum OPG were calculated on 9th day post infection in all 
groups. OPG count was lower in group A2 and A3 as compared to A1 and control A4; although 
difference between groups A2 and A3 was non-significant (Table 4.8; Figure 4.8). 
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b. Daily weight gains post challenge  
The average daily weight gains (gm±SE) of all the groups were calculated from day 
3rd to 12th post challenge (Table 4.9; Figure 4.9). Weight gains were significantly higher 
(p<0.05) in chickens of experimental group A2 administered with A. vera polysaccharides at 
dose rates of 200 mg/kg of body weight as compared to chickens of A3, A1 and control 
groups; whereas,  difference in weight gains in chickens of groups A3 and A1 was statistically 
non-significant (p>0.05). 
c. Per cent protection and mortality post challenge in experimental and control groups  
Maximum protection (70%) was observed in groups administered with A. vera 
polysaccharides at the dose rate of 200mg/kg body weight followed by group A3 (60%) and 
group A1 (55%). Chickens in control group A4 gave protection (30%).  The protection 
difference among experimental groups was statistically significant (p<0.05) (Table 4.10; 
Figure 4.10).  
Further, chickens in experimental groups A2 and A3 were comparatively active than 
control, took normal feed and water intake as compared to control group A4, which were 
depressed with ruffled feathers and took less feed and water. 
d. Lesion scoring and per cent protection against lesions 
From day 6th to 12th post challenge, All survived and dead chickens were monitored 
for lesion scoring of caeca and intestine on a scale from 0 to 4. Experimental groups showed 
lesser lesions as compared to control and similarly showed more protection against lesions. 
Among experimental groups, chickens of group A2 showed least severe caecal lesion scores 
(2.55) followed by A1 (3.05) and A3 (3.2) as compared to chickens in control group, which 
showed severe lesion scores (3.87). 
Per cent protection against caecal lesions was calculated to estimate the protective 
efficacy of A. vera polysaccharides in experimental and control groups against lesions caused 
by Eimeria challenge. Chickens of group A2 showed maximum per cent protection against 
caecal lesions (36.25%) followed by group A1 (23.75%), A3 (20%) and control group A4 
(3.25%) (Table 4.11; Figure 4.11).   
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Chickens of experimental groups showed minimum lesion scores in intestines for 
group A2 (2.025) followed by group A3 (2.325) and A1 (2.675); whereas, control group A4 
showed highest mean lesion score of (3.5). Similarly, results of per cent protection against 
intestinal lesions showed maximum protection of 49.375 % in group A2, followed by group 
A3 (41.875%), A1 (33.125%) and control group showed least protection of 12.5%. Maximum 
(85%) chickens in control group showed severe lesions (3.0-4.0); moderate lesions (2.0) were 
also observed in 15 per cent chickens. Among experimental groups, chickens of group A2 
developed least severe lesions (50%) followed by A3 (60%) and A1 (80%). A similar trend 
was observed in case of intestinal lesion scores.  
e. Anticoccidial index for polysaccharides 
Relative rate of weight gain, survival rate, lesion value and oocyst clearance rate were 
determined to calculate anticoccidial index (AI). Maximum AI was calculated in chickens of 
group A2 (239.63) administered with A. vera polysaccharides (200mg/kg body weight) 
followed by group A3 (195.31), A1 (159.75) and control A4 (36.57) (Table 4.12; Figure 4.12). 
4.1.6. Organ-body weight ratios post challenge  
The organ-body weight ratios of immune organs including spleen, thymus, caecal 
tonsils and bursa of fabricius were calculated on day 12th post challenge with mixed Emeria 
species. All groups showed statistically similar organ-body weight ratios (p>0.05) except 
spleen. Spleen of control group showed  higher organ-body ratio as compared to groups 
administered with A. vera polysaccharides and difference was statistically significant 
(p<0.05) (Table 4.13; Figure 4.13). 
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Figure 4A1: Chromatogram showing the peaks of monosaccharides in Aloe vera     
           polysaccharides at different retention times 
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Chromatograms of monosaccharides standards are shown in annexure IV 
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Table 5A:   Quantitative analysis of monosaccharides detected in the hydrolyzed 
sample of Aloe vera polysaccharides 
Monosaccharide Retention Time 
(minutes) 
Area 
(mV.s) 
Height 
(mV) 
Quantity 
(molar %) 
Maltose 9.423 11.837 0.540 0.04 
Glucose 11.080 35.252 0.605 0.11 
Mannose 12.550 36.885 0.612 0.02 
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Table 4.1:  In vivo lymphoproliferative response to PHA-P in experimental and control                
        chickens 
Groups Increase in thickness 
 24 hrs. 
(mm±SE) 
48 hrs. 
(mm±SE) 
72 hrs. 
(mm±SE) 
A1 1.00±0.12ab 0.76±0.04b 0.61±0.03bc 
A2 1.13±0.11a 0.92±0.02a 0.81±0.07a 
A3 1.09±0.15ab 0.89±0.02ab 0.78±0.05a 
A4 0.68±0.03b 0.62±0.01c 0.40±0.03c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.1:  In vivo lymphoproliferative response to PHA-P in experimental and 
control chickens 
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Table 4.2: In vitro lymphoproliferative response to Concanavalin-A in experimental         
        and control chickens 
Groups Stimulation index post administration of Aloe vera 
polysaccharides 
 Day 7th 
(MeanOD+SE) 
Day 14th 
(MeanOD+SE) 
A1 0.38±0.04b 0.39±0.03b 
A2 0.74±0.02a 0.75±0.02a 
A3 0.75±0.01a 0.74±0.02a 
A4 0.28±0.01c 0.32±0.01c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.2:  In vitro lymphoproliferative response to Concanavalin-A in experimental  
         and control chickens 
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Table 4.3: Carbon particle clearance assay in experimental and control chickens 
Groups Carbon particle clearance assay post administration of Aloe  vera 
polysaccharides 
 Clearance index (K) 
(MeanOD±SE) 
Phagocytic index  (α) 
(MeanOD±SE) 
A1 0.0106±0.0039b             69.3054±13.6106b 
A2 0.0073±0.0024c             94.8283±9.3211a 
A3  0.0124±0.0019ab             51.2677±10.2013bc 
A4 0.0185±0.0040a             48.5554±9.8143c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1= A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
Figure 4.3 (a): Carbon particle clearance assay (Clearance Index K) 
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Figure 4.3 (b): Carbon particle clearance assay (Phagocytic Index α) 
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A1= A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
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Table 4.4: Antibody response to sheep red blood cells in experimental and control             
       chickens 
-------Total anti-SRBCs antibody titer---- 
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
 
Group Day 7 PPI Day 14 PPI Day 7 PSI Day 14 PSI 
A1 42.22 42.22 64 48.50 
A2 73.52 55.72 84.45 64 
A3 64 42.22 73.51 55.71 
A4 32 24.25 27.85 13.92 
----------Immunoglobulin-M-------- 
A1 28.29 17.97 36.14 11.74 
A2 52.40 18.95 47.69 15.49 
A3 48 14.36  45.65 13.49 
A4 19.87 8.25 15.73 4.73 
-------Immunoglobulin-G----- 
  A1 13.92 24.25 27.85 36.75 
A2 21.11 36.75 36.75 48.50 
A3 16 27.85 27.85 42.22 
A4 12.12 16 12.12 9.18 
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Figure 4.4 (a-d): Antibody response to sheep red blood cells in experimental and control  
                  chickens 
 
a. At day 7th post primary injection 
 
 
b. At day 14th post primary injection 
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c. At day 7th post secondary injection 
 
 
d. At day 14th post secondary injection 
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Table 4.5: Organ-body weight ratios on 14th day post administration of Aloe vera      
       polysaccharides in experimental and control chickens 
Groups Thymus 
(Mean±SE) 
Spleen 
(Mean±SE) 
Bursa 
(Mean±SE) 
Caecal tonsils 
(Mean±SE) 
A1 0.36±0.011b 0.23±0.011 0.26±0.008 0.09±0.008 
A2      0.38±0.008a 0.23±0.008 0.26±0.006 0.09±0.010 
A3    0.37±0.0158ab 0.23±0.007  0.26±0.0100 0.09±0.007 
A4 0.35±0.008b 0.22±0.006 0.25±0.016 0.08±0.007 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.5: Organ-body weight ratios on 14th day post administration of Aloe vera     
         polysaccharides in experimental and control chickens 
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Table 4.6: Weekly (1st-6th) weight gains in experimental and control groups 
Weeks 
A1 A2 A3 A4 
(Mean±SE) (Mean±SE) (Mean±SE) (Mean±SE) 
1st 123.33±15.28
b 118.00±7.21c 126.67±15.28a 110.00±10.00d 
2nd 220.00±20.00
c 246.67±35.12b 296.67±15.28a 246.67±15.28b 
3rd 356.67±15.28
c 446.67±15.28a 426.67±25.17ab 350.00±50.00c 
4th 843.33±45.09
c 950.00±50.00b 1010.00±36.06a 816.67±76.38d 
5th 1166.67±76.38
c 1276.67±25.17ab 1383.33±76.38a 1200.0±132.9bc 
6th 1566.67±28.87
c 1683.33±104.0b 1753.33±174.7a 1500.00±152.7c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A.  vera polysaccharides @ 100mg/kg of BW 
A2=A.  vera polysaccharides @ 200mg/kg of BW 
A3=A.  vera polysaccharides @ 300mg/kg of BW 
A4=Control 
Figure 4.6: Weekly (1st-6th) weight gains in experimental and control groups 
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Table 4.7: Results of weekly FCR post administration of Aloe vera polysaccharides in 
experimental and control chickens 
Weeks A1 A2 A3 A4 
Feed Conversion Ratios 
1st 2.21 2.17 2.07 2.03 
2nd 2.16 2.01 2.03 2.12 
3rd 2.04 1.97 1.98 2.15 
4th 2.05 1.96 1.97 2.19 
5th 2.01 1.98 1.94 2.17 
6th 2.01 1.96 1.95 2.16 
A1=A.  vera polysaccharides @ 100mg/kg of BW 
A2=A.  vera polysaccharides @ 200mg/kg of BW 
A3=A.  vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.7: Results of weekly FCR post administration of Aloe vera polysaccharides in     
        experimental and control chickens 
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Table 4.8: Oocysts per gram of droppings post challenge in experimental and                 
       control chickens 
Days 
Groups 
A1 
(Mean±SE) 
A2 
(Mean±SE) 
A3 
(Mean±SE) 
A4 
(Mean±SE) 
4th 9843.33±577.09b 8519.33±800.18d 8862.00±236.25c 34933.33±1866.58a 
5th 13838.00±2170.67b 11906.67±674.86dc 12290.00±121.24c 57629.33±5783.97a 
7th 45273.33±3896.29b 40940.00±1989.07d 41986.67±1364.89c 227135.33±23038.51a 
9th 95462.67±3354.00b 66083.33±48356.33dc 91125.33±6720.55bc 383179.33±20736.35a 
11th 70242.67±5000.97b 64996.00±4152.12c 63432.67±4626.43d 128292.67±25891.74a 
12th 38113.33±4266.72b 34766.67±4467.33dc 36326.00±2228.15c 66797.33±8571.50a 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
Figure 4.8: Oocysts per gram of droppings post challenge in experimental and control  
        chickens 
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Table 4.9:  Daily weight gains from day 3rd to 12th post challenge in experimental and 
control chickens 
Days Groups 
 
A1 
(gm±SE) 
A2 
(gm±SE) 
A3 
(gm±SE) 
A4 
(gm±SE) 
3rd 16.89±0.05b 19.61±1.50a 16.55±0.62b 16.72±0.92b 
4th 16.72±0.56b 19.78±0.75a 17.55±0.48ab 15.22±0.33c 
5th 17.31±0.82b 19.44±0.93a 15.89±0.50c 13.22±0.44d 
6th 15.83±0.67b 18.44±0.84a 16.05±0.59b 11.56±0.52c 
7th     13.39±0.46c     16.78±0.79a     14.89±0.42b  11.89±0.60d 
8th 12.39±0.60c 16.11±0.66b 14.39±1.00a 9.55±0.41d 
9th 12.09±1.02b 15.78±1.06a 13.39±0.85b 9.55±0.58c 
10th 13.05±1.01b 16.61±0.63a 13.39±0.56b 10.55±0.50c 
11th 12.89±0.40b 16.78±0.71a 13.89±0.71b 11.55±0.43c 
12th 14.39±0.82b 16.94±0.45a 15.12±0.24ab 12.89±0.52c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A.vera polysaccharides @ 100mg/kg of BW 
A2=A.vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
Figure 4.9:  Daily weight gains from day 3rd to 12th post challenge in experimental and 
control chickens 
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Table 4.10: Per cent protection and mortality post challenge in experimental and      
        control chickens 
 A1 A2 A3 A4 
Protection (%) 55 70 60 30 
Mortality (%) 45 30 40 70 
A1= A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.10:  Per cent protection post challenge in experimental and control chickens  
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Table 4.11: Lesion scoring and per cent protection against lesions in experimental and 
         control chickens 
Groups  Lesion Scoring of Birds Protection against lesions 
 0 1 2 3 4 (%) 
Caeca 
A1 0 5 6 11 18 23.75 
A2 0 8 14 6 12 36.25 
A3 0 0 8 16 16 20 
A4  0 0 5 11 28 3.25 
Intestine 
A1 0 11 6 8 15 33.125 
A2 0 12 9 5 9 49.375 
A3 0 16 7 5 12 41.875 
A4  0 0 2 16 22 12.5 
A1 =A.  vera polysaccharides @ 100mg/kg of BW 
A2=A.  vera polysaccharides @ 200mg/kg of BW 
A3=A.  vera polysaccharides @ 300mg/kg of BW 
A4=Control 
Figure 4.11: Per cent protection against lesions in experimental and control chickens 
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Table 4.12:  Anticoccidial index for polysaccharides 
Groups Relative rate of   wt. 
gains 
Survival 
rate 
Lesion 
value 
Oocyst 
clearance 
rate 
 ACI 
A1 162.567 0.55 2.675 0.696 159.75  
A2 241.696 0.7 2.025 0.746 239.63  
A3 197.756 0.6 2.325 0.717 195.31  
A4 40.14 0.3 3.5 0 36.57  
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.12:  Anticoccidial index for polysaccharides 
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Table 4.13: Organ-body weight ratios post challenge in experimental and control     
         chickens 
Groups Thymus 
(Mean±SE) 
Spleen 
(Mean±SE) 
Bursa  
(Mean±SE) 
Caecal tonsils 
(Mean±SE) 
A1 0.37±0.01 0.27±0.02c 0.26±0.01 0.09±0.01 
A2 0.38±0.01 0.28±0.01b 0.25±0.01 
0.08±0.01 
A3 0.37±0.01 0.28±0.01b 0.26±0.01 0.08±0.01 
A4 0.36±0.01 
0.29±0.01a 0.25±0.01 0.07±0.01 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
A1=A. vera polysaccharides @ 100mg/kg of BW 
A2=A. vera polysaccharides @ 200mg/kg of BW 
A3=A. vera polysaccharides @ 300mg/kg of BW 
A4=Control 
 
Figure 4.13: Organ-body weight ratios post challenge in experimental and control    
           chickens 
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Experiment-II 
4.2. Isolation and characterization of Aloe vera proteins  
 Proteins extraction from A. vera were quantified in duplicate by Bradford assay and 
concentration was ranged from 22.6-26 µg/ml. (Table 4B, B1; Figure 4B). Automated 
electrophoretic analysis of the isolated proteins revealed the presence of proteins of 
molecular weight 1 and 6kD. Three samples were analyzed, which showed similar results 
(Table 4B2; Figure 4C1, C2). 
4.2.1. Immunological evaluation 
For immunological evaluation both cell mediated and humoral immune responses 
were detected. lymphoproliferative response to PHA-P and carbon particle clearance assay 
were used to demonstrate in vivo cell mediated immune responses; whereas, in vitro cell 
mediated immune response was detected by lymphoproliferative response to Concanavalin-A 
(Con-A). Humoral immune response was detected by antibody response to sheep red blood 
cells. 
4.2.2a. Cell mediated immune responses 
i. In vivo lymphoproliferative response (mm) to Phytohaemagglutinin-P (PHA-P)  
The amplitude of toe-web swelling was measured at 24, 48 and 72 hours post PHA-P 
injection (mm±SE) in experimental and control groups.  A. vera proteins administered groups 
showed significantly higher response in all experimental groups as compared to control 
(p<0.05). Maximum swelling was observed at 24 hours post PHA-P injection in all the 
groups (treated and control) followed by 48 and 72 hours. Group B2, which was administered 
with A. vera proteins at the dose rate of 200mg/kg body weight showed maximum swelling 
(0.81±0.04) followed by group B3 (0.78±0.02), B1 (0.72±0.05) and control (0.63±0.04). The 
difference between groups was significantly higher in group B2 but it was similar to group 
B3. At 48 hours post PHA-P injection, groups B2 and B3 showed PHA-P response of 
0.73±0.03 and 0.72±0.03. Their response was significantly higher response as compared to 
B1 (0.65±0.06) and B4 (0.58±0.03). The difference between groups B2 and B3 were 
statistically similar. At 72 hours post PHA-P injection, maximum swelling was observed in 
chickens of group B2 (0.63±0.03) followed by group B3 (0.61± 0.02), B1 (0.57±0.07) and B4 
(0.40±0.03). Statistically results at 24 hours were similar to observed at 72 hours post PHA-P 
injection (Table 4.14; Figure 4.14).  
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ii. In vitro lymphoproliferative response to Concanavalin-A in experimental and control 
chickens 
In vitro lymphoproliferative response to concanavalin-A was detected at 7th and 14th 
day post administration of A. vera proteins at graded doses in all groups by 
lymphoblastogenic response of chicken peripheral blood  lymphocytes (PBLs) to Con-A. All 
treated groups showed significantly higher (p<0.05) response in the chickens PBLs as 
compared to control group on both day 7th and 14th post administration of A. vera proteins. 
However, among the treated groups, chickens administered with A. vera proteins at the dose 
rate of 200 and 300 mg/kg of body weight showed significantly higher (p<0.05) response as 
compared to those administered with A. vera proteins at dose rate of 100 mg/kg of body 
weight. Statistically group B2 at 14th day showed response similar to group B3 and group B1 
(Table 4.15; Figure 4.15). 
iii. Carbon particle clearance assay in experimental and control chickens 
On 14th day post administration of A. vera proteins, carbon particle clearance assay 
was performed to check the phagocytic activity of chicken macrophages. The clearance index 
(K), phagocytic index (α) and immune organ index (organ-body weight ratios) were 
calculated at 3 and 15 minutes post injection of  India ink. 
The results of clearance index showed significantly higher clearance index in control 
group B4 (0.027±0.002) and all the other medicated groups showed low clearance index 
values indicating less carbon particles in blood. Among treated groups with A. vera proteins 
at graded doses group B2 showed lowest K value (0.006±0.001) followed by group B1 
(0.017±0.002) and B3 (0.019±0.001). B3 and B1 response was statistically similar (Table 
4.16; Figure 4.16 a).  
The results of phagocytic index (α) showed significantly higher response in all three 
medicated groups as compared to control. Maximum response was observed in group B2 
(89.635±7.649), which was administered with A. vera proteins at the dose rate of 200mg/kg 
body weight, followed by B1 (66.734±12.245) and B3 (50.481±8.477). Statistically group B2 
showed significantly higher phagocytic index followed by group B1, whereas B3 showed 
response, which was similar to group B1 and B4 (Table 4.16; Figure 4.16 b). 
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4.2.2b. Humoral Immune responses 
i. Antibody response to sheep red blood cells (SRBCs) 
Humoral immune responses were detected by microplate haemagglutination assay in 
chickens of experimental and control groups on day 7th and 14th post primary and secondary 
injections of SRBCs; and results were calculated in terms of geomean titers (GMT) (Table 
4.17; Figure 4.17 a-d). 
Total anti-SRBCs antibody titer 
 Highest geomean anti-SRBCs antibody titer (GMT 64.0) was detected in chickens 
administered with A. vera extracted proteins @ 300 mg/kg body weight followed by chickens 
in group B2 (GMT 55.72), B1 (GMT 32) and control group B4 (GMT 27.86) at day 7th PPI. At 
day 14th PPI, chickens in all the groups showed similar trend of antibody titer. Moreover, 
total anti-SRBCs Igs titers at day 7th and 14th PSI were also at the same pattern as observed 
on day 7th and 14th PPI. 
IgM anti-SRBCs antibody titer 
 At day 7th PPI, highest IgM anti-SRBC antibody titers were detected in group B3 
(GMT 39.74), followed by B2 (GMT 37.34), B1 (GMT 21.44) and control group B4 (GMT 
18.69). At day 14th PPI, chickens in group B3 (GMT 20.64) showed the highest antibody titer 
followed by those of group B2 (GMT 17.97), B1 (GMT 9.48) and control group (GMT 7.18); 
and showed similar trend on day 7th and 14th PSI.    
IgG anti-SRBCs antibody titer 
Anti-SRBCs IgG titers showed a similar trend to total anti-SRBCs Igs titers as 
detected on both days 7th and 14th post primary and post secondary injections of SRBCs 
(Table 4.17; Figure 4.17 a-d). 
4.2.3. Effect on the development of lymphoid organs of chickens 
The organ-body weight ratios of lymphoid organs (immune organ index) were 
calculated on day 14th post administration of A. vera proteins. Immune organs observed were 
bursa of fabricius, spleen, thymus and caecal tonsils. Experimental groups showed higher per 
cent organ-body weight ratios except spleen as compared to control group; whereas the 
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statistical difference was non-significant (p>0.05)  in immune organs of all groups except 
thymus of experimental groups showed statistically significant response as compared to 
control (Table 4.18; Figure 4.18). 
4.2.4. Effect on body weight gains and feed conversion ratios (FCR) 
Chickens from all groups were weighed from week 1st to 6th; feed consumed by each 
group was also recorded. Experimental groups (B1, B2 and B3) showed statistically 
significant weight gains as compared to control (p<0.05). Maximum weight gains (gm±SE) 
at 6th week were observed in group administered with A. vera proteins (Table 4.19; Figure 
4.19). Among experimental groups, maximum weight gain was observed in group B2 
(1700.00±50.00) followed by B3 (1630.00±81.85), B1 (1556.67±11.55) and control group B4 
(1503.33±20.2). Similarly, all experimental groups administered with A. vera proteins 
showed better FCR as compared to control. FCR was calculated on weekly basis for all 
experimental and control groups from week 1st to 6th. On the whole, results of FCR was 
better in group B3 (A. vera proteins @ 300 mg/kg body weight) followed by group B2, B1 and 
control group B4 (Table 4.20; Figure 4.20). 
4.2.5. Challenge experiment 
a. Oocysts per gram (OPG) of droppings post-challenge in experimental and control 
chickens 
Experimental groups administered with A. vera proteins showed significantly lower 
OPG as compared to control in challenge experiment. OPG values of control group were 
significantly higher (p<0.05) than experimental groups. Among experimental groups, lowest 
OPG was observed in group B2 (proteins @ 200mg/kg body weight) followed by B3, B1 and 
control; although statistically response was similar between group B2 and B3 (Table 4.21; 
Figure 4.21). 
b. Daily weight gains post challenge  
Daily weight gains (gm±SE) of all the groups were calculated from day 3rd to 12th post 
challenge. The average body weight gains were significantly higher (p<0.05) in chickens of 
experimental groups B2 administered with A.  vera proteins (@ 200 mg/kg of body weight) 
as compared to chickens of group B3, B1 and control groups; whereas,  difference in weight 
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gains in chickens of groups B3 and B1 was statistically non-significant (p>0.05) (Table 4.22; 
Figure 4.22). 
c. Per cent protection post challenge in experimental and control groups  
 Chickens of experimental groups showed higher protection against coccidiosis post 
challenge as compared to control.  Maximum protection (57.5 %) was observed in chickens 
administered with A.  vera proteins @ 200 mg/kg body weight (group B2) followed by group 
B3 (52.5%), B1 (50%) and control group B4 (25%). The chickens of experimental groups 
were comparatively active and took more feed and water as than control group. The per cent 
protection among experimental groups was statistically significant (p<0.05) (Table 4.23; 
Figure 4.23). 
d. Lesion scoring and per cent protection against lesions  
Lesion score and per cent protection against lesions were calculated in all groups 
challenged with mixed Eimeria species (local isolates). All survived and dead chickens were 
monitored for lesion scoring of caeca and intestine on a scale from 0 to 4. Experimental 
groups showed lesser lesion as compared to control and showed higher protection against 
lesions. Among experimental groups, chickens of group B2 (3.175) showed least severe 
caecal lesion score followed by B3 (3.325), B1 (3.4). Further, chickens in control group 
showed severe lesion score (3.5) (Table 4.24; Figure 4.24). 
 Per cent protection against caecal lesions was calculated to demonstrate the 
protective efficacy of A. vera proteins in experimental and control groups against lesions 
caused by mixed species Eimeria challenge. Chickens of group B2 showed maximum per 
cent protection against lesions (20.625%) followed by group B3 (16.875%), B1 (15%) and 
control group B4 (12.5%) (Table 4.24; Figure 4.24).   
Chickens of experimental groups showed minimum lesion scores in intestines for 
group B2 (2.425) followed by group B3 (2.775) and B1 (3.075); whereas, control group B4 
showed highest mean lesion score of (3.475). Similarly, results of per cent protection against 
intestinal lesions showed maximum protection (39.376%) in group B2, followed by group B3 
(30.625%), B1 (23.125%), and control group (13.125%). In control group, maximum 
chickens (90%) showed severe (3.0-4.0); whereas 10 % chicken showed moderate (2.0) 
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intestinal lesions. In group B2, 42.5% chickens develop severe lesions; 30% moderate and 
27.5% showed mild to moderate lesions (1.0-2.0). 
e. Anticoccidial index for proteins 
Maximum anticoccidial index was calculated for group B2 (172.26) followed by 
group B3 (162.37), B1 (103.26) and control group B4 (17.85) (Table 4.25; Figure 4.25). 
4.2.6. Organ-body weight ratios post challenge in experimental and control groups  
The organ-body weight ratios of immune organs including thymus, spleen, bursa of 
fabricius and caecal tonsils were calculated. All the groups showed statistically similar 
(p>0.05) response (Table 4.26; Figure 4.26). 
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Table 4B: Bradford assay for protein quantification 
Standards 
Concentration 100 200 300 400 500 600 700 800 900 1000 
Absorbance 0.498 0.526 0.54 0.572 0.581 0.59 0.592 0.617 0.657 0.663 
 
 
Figure 4B: Standard curve for protein quantification by Bradford assay 
 
 
Table 4B1: Results of protein sample by Bradford assay 
Absorbance 0.180 0.193 
Concentration (µg/ml) 22.6 26.0 
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Table 4B2: Profile of proteins isolated from Aloe vera by Automated Electrophoresis 
system 
Peak Number Migration Time (sec) Mol. Wt. 
(kDa) 
Corrected Area 
1.  12.20 0.00 34.59 
2.  13.55 1.00 27.35 
3.  14.55 0.00 1835.10 
4.  17.55 0.00 11.00 
5.  19.90 6.00 2515.88 
6.  43.20 0.00 1.07 
7.  44.00 0.00 22.22 
8.  54.85 0.00 1.54 
9.  59.60 0.00 2.36 
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Figure 4C1: Profile of proteins isolated from Aloe vera 
 
 
Figure 4C2:  Profile of proteins isolated from Aloe vera 
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Table 4.14: In vivo lymphoproliferative response to PHA-P in experimental and 
control chickens 
Groups Increase in thickness (mm) 
 24 hrs. 
(mm±SE) 
48 hrs. 
(mm±SE) 
72 hrs. 
(mm±SE) 
B1 0.72±0.05b 0.65±0.06b 0.57±0.07b 
B2 0.81±0.04a 0.73±0.03a 0.63±0.03a 
B3 0.78±0.02ab 0.72±0.03a 0.61±0.02ab 
B4 0.63±0.04c 0.58±0.03c 0.40±0.03c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A.vera proteins @ 300mg/kg of BW 
B4=Control 
 
Figure 4.14: In vivo lymphoproliferative response to PHA-P in experimental and 
control chickens 
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Table 4.15:  In vitro lymphoproliferative response to Concanavalin-A in experimental 
and control chickens 
Groups Stimulation index post administration of Aloe vera proteins 
 Day 7th 
(MeanOD+SE) 
Day 14th 
(MeanOD+SE) 
B1 0.364±0.02b 0.380±0.02b 
B2 0.382±0.02a 0.388±0.04ab 
B3 0.378±0.04a 0.394±0.03a 
B4 0.260±0.04c 0.280±0.04c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A.vera proteins @ 300mg/kg of BW 
B4=Control 
 
 
Figure 4.15:  In vitro lymphoproliferative response to Concanavalin-A in experimental 
and control chickens 
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Table 4.16: Carbon particle clearance assay in experimental and control chickens 
Groups Carbon particle clearance assay post administration of Aloe vera 
proteins  
 Clearance index (K) 
(MeanOD±SE) 
Phagocytic index  (α) 
(MeanOD±SE) 
B1 0.017±0.002b 66.734±12.245b 
B2 0.006±0.001c 89.635±7.649a 
B3 0.019±0.001b 50.481±8.477bc 
B4 0.027±0.002a 47.812±8.150c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4=Control 
 
 
Figure 4.16 (a): Carbon particle clearance assay (Clearence Index) 
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Figure 4.16 (b): Carbon particle clearance assay (Phagocytic Index) 
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B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4=Control 
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Table 4.17:  Antibody response to sheep red blood cells in experimental and   
 control chickens 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4=Control 
--------Total anti-SRBCs antibody titer-------- 
Groups Day 7 PPI Day 14 PPI Day 7 PSI Day 14 PSI 
B1 32 27.86 55.72 48.50 
B2 55.72 42.22 73.52 64 
B3 64 48.50 84.45 73.52 
B4 27.86 21.11 32 27.86 
----------Immunoglobulin-M-------- 
B1 21.44 9.48 31.46 16.50 
B2 37.34 17.97 45.66 21.78 
B3 39.74 20.64 47.69 25.01 
B4 18.69 7.18 21.44 6.74 
-------Immunoglobulin-G----- 
  B1 10.56 18.37 24.25 32 
           B2 18.37 24.25 27.85 42.22 
           B3 24.25 27.85 36.76 48.50 
           B4 9.19 13.93 10.56 21.11 
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Figure 4.17(a-d): Antibody response to sheep red blood cells in experimental and 
control chickens 
 
a. At day 7th post primary injection 
 
 
b. At day 14thpost primary injection 
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                                                  c. At day 7th post secondary injection 
 
 
 
d. At day 14thpost secondary injection 
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Table 4.18:  Organ-body weight ratios on day 14th post administration of Aloe vera 
proteins in experimental and control chickens 
Groups Thymus 
(Mean±SE) 
Spleen 
(Mean±SE) 
Bursa  
(Mean±SE) 
Caecal tonsils 
(Mean±SE) 
B1 0.36±0.03a 0.20±0.01 0.24±0.02 0.09±0.01 
B2 0.37±0.02a 0.22±0.02 0.25±0.02 0.08±0.01 
B3 0.36±0.01a 0.22±0.02 0.25±0.01 0.08±0.01 
B4 0.34±0.01b 0.23±0.00 0.24±0.01 0.08±0.01 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A.veraproteins @ 100mg/kg of BW 
B2=A.vera proteins @ 200mg/kg of BW 
B3=A.vera proteins @ 300mg/kg of BW 
B4=Control  
 
Figure 4.18:  Organ-body weight ratios on day 14th post administration of Aloe vera 
proteins in experimental and control chickens 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Thymus Spleen Bursa C. tonsils
O
rg
an
-b
o
d
y 
w
e
ig
h
t 
ra
ti
o
s
Lymphoid organs
B1 B2 B3 B4
 
 
73 
  
Table 4.19:  Weekly (1st-6th) weight gains in experimental and control chickens  
Weeks 
B1 B2 B3 B4 
(Mean±SE) (Mean±SE) (Mean±SE) (Mean±SE) 
1st 
120.00±10.00b 130.00±10.00a 128.33±7.64ab 121.67±7.64b 
2nd 
231.67±18.93c 271.67±2.89a 265.00±5.00b 263.33±12.5bc 
3rd 
360.00±20.00b 416.67±12.58ab 426.67±25.17a 350.00±50.00b 
4th 
856.67±28.87c 985.00±22.91a 920.00±30.0ab 836.67±55.08d 
5th 
1136.67±32.1bc 1360.00±52.9a 1270.00±34.6ab 1063.33±77.6c 
6th 
1556.67±11.5b 1700.00±50.0a 1630.00±81.85ab 1503.33±20.2b 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4=Control  
 
Figure 4.19:  Weekly (1st-6th) weight gains in experimental and control chickens 
 
0
200
400
600
800
1000
1200
1400
1600
1800
2000
1st 2nd 3rd 4th 5th 6th
W
e
e
kl
y 
w
e
ig
h
t 
ga
in
s
Weeks post administration of Aloe vera proteins
B1 B2 B3 B4
 
 
74 
  
Table 4.20:  Results of weekly FCR post administration of Aloe vera proteins in 
experimental and control chickens 
Weeks B1 B2 B3 B4 
Feed Conversion Ratios 
1st 2 2.01 2.01 2.12 
2nd 2.2 1.99 2.01 2.11 
3rd 2.17 1.98 1.98 2.12 
4th 2.14 1.97 1.97 2.13 
5th 2.11 1.97 1.98 2.14 
6th 2.08 1.95 1.94 2.14 
B1=A.  vera proteins @ 100mg/kg of BW 
B2=A.  vera proteins @ 200mg/kg of BW 
B3=A.  vera proteins @ 300mg/kg of BW 
B4=Control  
 
Figure 4.20:  Results of weekly FCR post administration of Aloe vera proteins in 
experimental and control chickens 
1.8
1.85
1.9
1.95
2
2.05
2.1
2.15
2.2
B1 B2 B3 B4
Fe
e
d
 C
o
n
ve
rs
io
n
 r
at
io
s
Groups
 
75 
  
Table 4.21:  Oocysts per gram of droppings post challenge in experimental and 
control chickens 
Days 
Groups 
B1 
(Mean±SE) 
B2 
(Mean±SE) 
B3 
(Mean±SE) 
B4 
(Mean±SE) 
4th 9900.33±577.09b 8576.67±799.80d 8919.67±235.09c 34991.33±1867.55a 
5th 13894.33±2169.60b 11964.33±673.80dc 12347.67±122.15c 58685.67±5150.63a 
7th 45329.67±3896.07b 40996.67±1988.66d 42043.33±1365.42c 227193.33±23039.01a 
9th 95519.33±3354.86b 66138.67±48360.06dc 91183.67±6719.70c 386569.67±15535.00a 
11th 70299.67±5000.97b 65053.00±4152.12c 63494.33±4634.43d 128683.00±25796.56a 
12th 38168.67±4267.31b 34824.33±4466.23dc 36382.33±2228.25c 67187.67±8379.42a 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A.vera proteins @ 100mg/kg of BW 
B2=A.vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4= Control  
 
Figure 4.21:  Oocysts per gram of droppings post challenge in experimental and 
control chickens 
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Table 4.22:  Daily weight gains in chickens from day 3rd to 12th post challenge in 
experimental and control chickens 
Days 
Groups 
 
B1 
(gm±SE) 
B2 
(gm±SE) 
B3 
(gm±SE) 
B4 
(gm±SE) 
3rd 15.00±1.00a 15.75±0.66a 14.67±0.76b 14.83±0.76b 
4th 14.83±0.52bc 16.00±1.00a 15.67±0.76b 13.33±1.53c 
5th 15.42±0.52a 15.67±0.58a 14.00±1.00b 11.33±0.58c 
6th 13.92±0.38b 14.67±0.76a 14.17±1.04a 9.67±0.58c 
7th 11.50±0.50b 13.00±1.00a 13.00±1.00a 10.00±1.00c 
8th 10.50±0.50b 12.33±1.04a 12.50±0.50a 7.67±0.58c 
9th 10.50±0.50b 12.00±1.00a 11.50±0.50a 7.67±1.53c 
10th 11.17±0.76b 12.83±0.76a 11.50±0.50b 8.67±1.15c 
11th 11.00±1.00b 13.00±0.50a 12.00±0.50ab 9.67±0.58c 
12th 12.50±0.50b 13.17±1.26a 12.50±0.87b 11.00±1.00c 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4= Control  
 
Figure 4.22:  Daily weight gains in chickens from day 3rd to 12th post challenge in 
experimental and control chickens  
 
  
77 
  
Table 4.23:  Per cent protection and mortality post challenge in experimental 
and control chickens  
Mortality and 
protection 
B1 B2 B3 B4 Chi square  
Birds Died 20 17 19 30 
4.698 
(p<0.195) 
% Mortality 50 42.5 47.5 75 
Birds Protected 20 23 21 10 
5.459 
(p<0.141) 
% Protection 50 57.5 52.5 25 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A.  vera proteins @ 100mg/kg of BW 
B2=A.  vera proteins @ 200mg/kg of BW 
B3=A.  vera proteins @ 300mg/kg of BW 
B4= Control  
 
Figure 4.23:  Per cent protection post challenge in experimental and control 
chickens  
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Table 4.24: Lesion scores and per cent protection against lesions in experimental and 
control chickens  
Groups  Lesion Scoring of Birds Protection against lesions 
` 0 1 2 3 4 (%) 
Caeca 
B1 0 0 4 16 20 15 
B2 0 0 10 13 17 20.625 
B3 0 0 6 15 19 16.875 
B4  0 0 5 10 25 12.5 
Intestine 
B1 0 0 15 3 18 23.125 
B2 0 11 12 6 11 39.756 
B3 0 0 14 6 15 30.625 
B4  0 0 4 13 23 13.125 
B1=A.  vera proteins @ 100mg/kg of BW 
B2=A.  vera proteins @ 200mg/kg of BW 
B3=A.  vera proteins @ 300mg/kg of BW 
B4= Control  
 
Table 4.24: Per cent protection against lesions in experimental and control chickens  
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Table 4.25:  Anticoccidial index for proteins  
Groups 
Relative rate of   wt. 
gains  
Survival 
rate         
Lesion 
value 
Oocyst 
clearance 
rate 
 ACI 
B1 
106.508 0.525 3.075 0.697 103.26  
B2 
176.178 0.575 2.425 0.748 172.26  
B3 
165.397 0.5 2.775 0.718 162.37  
B4 
21.4 0.25 3.475 0 17.85  
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg of BW 
B4= Control  
 
Figure 4.25:  Anticoccidial index for proteins 
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Table 4.26: Organ-body weight ratios post challenge in experimental and control 
chickens 
Groups Thymus 
(Mean±SE) 
Spleen 
(Mean±SE) 
Bursa 
(Mean±SE) 
Caecal tonsils 
(Mean±SE) 
B1 0.35±0.02 0.24±0.02 0.25±0.01 0.094±0.01 
B2 0.36±0.01 0.25±0.02 0.27±0.02 0.096±0.02 
B3 0.37±0.02 0.24±0.02 0.25±0.01 0.094±0.004 
B4 0.35±0.02 0.25±0.02 0.24±0.02 0.092±0.01 
Means sharing similar letters in a column are statistically non-significant (p>0.05) 
B1=A. vera proteins @ 100mg/kg of BW 
B2=A. vera proteins @ 200mg/kg of BW 
B3=A. vera proteins @ 300mg/kg wof BW 
B4= Control  
 
Figure 4.26: Organ-body weight ratios post challenge in experimental and control 
chickens 
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CHAPTER 5 
DISCUSSION  
 
Many plants and their products have shown biological response modifying (BRM) 
activities including Angelica gigas, Cissampelos pareira, Astragalus membranaceus, 
Mangifera indica, Ganoderma lucidum, Ocimum sanctum, Zingiber officinale, Phyllanthus 
emblica, Allium sativum, Curcuma longa, Nyctanthus arbor-tritis, Vernonia amygdalina, 
Azadirachta indica, Musa paradisiacal and Aloe (A.) vera (Minja, 1989; Nundkumar and 
Ojewole, 2002; Fajimi and Taiwo, 2005; Githiori et al., 2006; Athanasiadou et al., 2007; 
Akhtar et al., 2008; Ismail and Asad, 2009; Anosa and Okoro, 2011; Patil et al., 2011; 
Akhtar et al., 2012). Keeping in view the encouraging results of A. vera as BRM in previous 
studies conducted in our laboratory (Akhtar et al., 2012), the current study was focused on 
the evaluation of specific A. vera derived biomolecules responsible for such biological 
activities.   
Biological response modifiers (BRMs) are compounds, which induce modifications in 
the functioning of the immune system and produce effects on the physiology of man and 
animals (Murthy et al., 2010). These include synthetic and natural preparations, which 
increase host responses to proliferative lesions and pathogens (Moore, 2004). BRMs either 
stimulate or suppress the immune responses of an organism against foreign bodies/antigens. 
The innate immune responses, considered to be first line of defense, include skin (physical 
component); complement, lysozyme and interferon (biochemical component); and 
neutrophils, macrophages and monocytes (cellular components). When these innate 
responses of immune system are inadequate against any infection then adaptive responses 
play their role by antibodies production and T-lymphocytes activation that are effector cells 
of cell mediated immunity. B-cell or humoral immunity produces circulating antibodies, 
which effect invading agents. Cell mediated immunity produce large number of activated 
lymphocytes to kill the invaders (Rang et al., 2003; Patil et al., 2011; Saroj et al., 2012). 
BRMs also reported to reduce the immunosuppressive effects due to medicines and 
simultaneously increased their effectiveness (Thakur et al., 2012 ). These modulate immune 
responses by stimulation or suppression, which prevents the development of diseases (Ghule 
et al., 2006). 
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Due to the encouraging results of A. vera as BRM and therapeutic agent in our 
previous studies, the current study was focused on A. vera (Aloe barbadensis Miller), which 
is one of the most ancient and extensively used medicinal plant (Davis et al., 1989). It has 
been used as folk and traditional medicines for centuries to treat and cure many diseases. It is 
native of northern parts of Africa but can be found across the world; and more than 500 
species of A. vera so far have been reported (Bawankar et al., 2012; Ahmed and Hussain, 
2013). Modern therapeutic use of A. vera was started in 1930s and up till now considerable 
research has been reported in many reputed journals. A. vera has been reported to cure 
variety of conditions including fever, burns and wound healing, gastrointestinal disorders, 
sexual vitality and fertility problems, inflammation, ulcer, arthritis, cancer, 
immunosupression, acquired immune deficiency syndrome and coccidiosis (Swaim et al., 
1992; Davis et al., 1994; Koo, 1994; Mwale et al., 2005; Bashir et al., 2011; Akhtar et al., 
2012). It was also considered as an effective tool to enhance immunity in broiler chicks and 
increasing microvilli density (Jinag et al., 2005; Yim et al., 2011; Akhtar et al., 2012).  
Moreover, various herbal preparations have showed immunomodulatory properties by 
stimulating immune responses (Chopra and Doiphode, 2002; Benny and Vanitha, 2004; 
Govindarajan et al., 2005; Spelman et al., 2006; Changkang et al., 2007; Kumar et al., 2012; 
Awais et al., 2011, 2013; Akhtar et al., 2012; Ramesh et al., 2012; Hussain et al., 2013). In 
this regard, A. vera is considered as one of the promising candidate having biological 
response modifying effects in different animal models (Djeraba and Quere, 2000; Lee et al., 
2001; Krishnan, 2006; Liu and Wang, 2007; Hamman, 2008; Madan et al., 2008; Sikarwar et 
al., 2010; Patil et al., 2011;  Chandu et al., 2011; Thakur et al., 2012; Kumar et al., 2012; 
Farahnejad et al., 2013).  
A. vera leaves contain three layers including rind, sap and gel (inner most layer). Its 
raw pulp contains about 98.5% water. Its gel is a clear substance made of 99-99.5% water 
(Eshun and He, 2004). Remaining portion contains glucomannans, vitamins, minerals, 
phenolic compounds, polysaccharides, lipids, proteins, amino acids, enzymes, saponins, 
salicylic acids, sugars and sterols (Boudreau and Beland, 2006; Surjushe et al., 2008; 
Balasubramanian and Narayanan, 2013).  
83 
  
 Clinical analysis of A. vera revealed that its pharmacological activities are mainly 
concentrated in leaf gel and rind portions. A. vera plants contained >75 bioactive compounds 
(Eshun and He, 2004; Joseph and Raj, 2010).  Its filet is 99.5 % water; whereas, 60% of 
remaining solids are polysaccharides. Most of the previous studies have focused on the 
evaluation of biological activities of two important components isolated from its leaves 
including anthraquinones (cathartic effect) and polysaccharides (effect on skin burns and 
incised wounds) (Zhang and Tizard, 1996; Chithra and Sjithlal, 1998); although only few 
reports are available on the elaboration of pharmacological mechanisms involved in such 
activities (Yao et al., 2009).  
 In this regard, therapeutic efficacy of A. vera  components had been reported in  
different animal models and human beings with promising results (Strickland, 2001; Agarry 
et al., 2005; Mwale et al., 2006), although limited work has been conducted on poultry 
(Mwale et al., 2005; Durrani et al., 2008; Akhtar et al., 2012; Yim et al., 2011). Keeping in 
view, the present project was designed to investigate the biological response modifying and 
therapeutic efficacy of A. vera polysaccharides and proteins in chickens. 
The whole current study was divided into two experiments; one for isolation and 
characterization of polysaccharides and its evaluation as biological response modifiers and 
therapeutic efficacy against avian coccidiosis. The second experiment was meant for protein 
isolation and quantification followed by their effects as biological response modifiers and 
therapeutic efficacy against coccidiosis. 
 Polysaccharides are carbohydrates, containing monosaccharide units joined to each 
other by glycosidic linkages; their structure ranges from linear to highly branched (Varki et 
al., 2008). They have diverse macromolecules structure, which enable them to hold vast 
biological information. Polysaccharides are different from nucleic acids and proteins by 
having repetitive structural features of monosaccharide polymers joined by glycosidic 
linkages (Ooi and Liu, 2000). Polysaccharides have shown biological response modifying 
activities (Xia and Cheng, 1988; Zhang and Tizard, 1996; Ishizuka et al., 2004; Ramberg et 
al., 2010) by modulating both humoral and cellular immune responses (Xue and Meng, 1996; 
Tzianabos, 2000; Vahedi et al., 2011). Polysaccharides have variable potential to influence 
various biological mechanisms and can modulate immune cells (Vilcek and Lee, 1991; 
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Duerksen-Hughes et al, 1992; Fidler and Kleinerman, 1993; Klostergaard, 1993; Gordon, 
2002). Mostly higher plant origin polysaccharides are relatively non-toxic and do not 
produce significant side effects, which are mostly associated with bacterial and synthetic 
immunomodulatory polysaccharide compounds. So, plant derived polysaccharides can be 
ideally used as immunomodulators, wound-healing and anti-tumor agents (Ovodov, 1998; 
Sherenesheva et al., 1998; Lazareva et al., 2002; Speranza et al., 2005; Mythilypriya et al., 
2008). Polysaccharides extracted from A. vera contributed a major role to its ethnomedicinal 
properties. A few reports regarding its polysaccharides constituents and their characterization 
are available (Chen et al., 2002; Yan et al., 2003; Vinson et al., 2005; Ai et al., 2008). 
Further, a little information about polysaccharides structure is reported; so, mostly it is not 
possible to determine how specifically polysaccharides influence macrophage activity for 
immunomodulation (Schepetkin and Quinn, 2006).  
A. vera is a rich source of many carbohydrate units including polysaccharide, 
mannose-6-phosphate and acemannan (Davis et al., 1994; Hamman, 2008). Acemannan (β-
(1, 4)-linked acetylated mannose) has shown immunomodulatory activities by macrophages 
activation; enhanced cytokine release, stimulated macrophages interactions and increased 
production of cytotoxic T-lymphocytes (Womble and Helderman, 1992; Roberts and Travis, 
1995). It also regulated macrophages phagocytosis and candidicidal activity (Stuart et al., 
1997); and potentiated antibody production against coxackie virus (Roberts and Travis, 
1995). Alcoholic precipitation of A. vera polysaccharides have shown significant radiation 
damage repair (Talmadge et al., 2004), wound healing (Tizard et al., 1994), pressure ulcers 
(Thomas et al., 1998), alveolar osteitis treatment after tooth extraction, modulate immune 
responses (Kahlon et al., 1991; Chinnah et al., 1992; Strickland et al., 1994; Karaca et al., 
1995; Pugh et al., 2001), antineoplastic (Harris et al.,1991; King et al., 1995; ) and antiviral 
(Montaner et al., 1996) activities.  
 In the current study, purified polysaccharides from A. vera were analyzed by using 
high performance liquid chromatography (HPLC). Sugars were identified by comparing 
retention times with the monosaccharide standards. Results showed the presence of three 
different monosaccharides including maltose, glucose and mannose in hydrolyzed solution of 
A. vera at retention times of 9.423, 11.080 and 12.55, respectively.  
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 Major polysaccharide containing Mannose named Acemannan has been isolated by 
various researchers (Hart et al., 1989). Acemannan is a linear polysaccharide made of (1, 4)-
linked mannosyl residues (Femenia et al., 1999). Mandal and Das (1980) isolated 
polysaccharides including arabinan, galactan and glucomannan. Ni et al. (2004) and Choi 
and Chung (2003) isolated polysaccharides from A. vera inner leaf gel including arabinan, 
glucogalactomannan, glucuronic acid, galactoglucoarabinomannan, arabinorhamnogalactan, 
galactogalacturan and galactan. Mannose and glucose were major isolated sugars between 
total 55% and 75% of total monosaccharides. The mannose residues probably came from 
acemannan, which has been found in large amounts in A. vera gel and filet (Fogleman et al., 
1992). Similar results were observed in the current study.  
 Yao et al. (2009) isolated  monosaccharide residues from A. vera  including D-glucose 
(45.6%), d-6-deoxy-mannose (0.2%), d-galactose (44.1%), d-fructose (0.1%) and a new 
polysaccharide from gel named galactoglucan (molecular weight 150 kDa). Moghaddasi and 
Verma (2011) described that A. vera contained two polysaccharides acemannan and 
glucomannan; whereas, saccharides were mannose, aldopentose, L-rhamnose and glucose. 
Acemannan is a major carbohydrate present in gel. It is water soluble and contains long 
chains of mannose polymer. It accelerates wound healing process. It modulates immune 
system by particularly activating macrophages and cytokines production (Peng et al., 1991). 
Chang et al. (2010) isolated mannose glucose and galactose from gel juice. A. vera gel 
extract contains 38% carbohydrates containing 4% glucose, 41% Galacturonic acid, 6% 
xylose, 39% mannose, 1% rhamnose, 6% galactose, 1% fucose, 1% arabinose (Luta et al., 
2009).   
 Present study indicated the presence of glucose, maltose and manose, which were also 
reported by Luta et al. (2009). In some other studies, different polysaccharide of variable 
molecular sizes have been isolated from A. vera (Leung, 1978; Femenia et al., 1999; 
Reynolds and Dweck, 1999; Chow et al., 2005) and this variability may be due to seasonal 
and cultivational variation as reported by Leung (1978). In another study, Pierce (1983) 
studied differences in cultivation and seasonal conditions that resulted in difference in A. 
vera gel nutritional contents. In some studies, technical differences during isolation and 
endogenous enzymes mediated polysaccharide degradation have been reported to be the 
cause of different polysaccharide molecular sizes (Chang et al., 2006). 
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As for as A. vera proteins are concerned, many of the researchers used whole leaf as a 
starting material to isolate proteins (Fujita et al., 1978; Yoshimoto et al., 1987; Koike et al., 
1995); and isolated glycoproteins of 29 kDa and 14kDa subunits, showed effects on wound 
healing (Fujita et al., 1978; Yagi et al., 1997; Choi et al., 2001), enhanced proliferation of 
human fibroblasts and hamster kidney cells (Yagi et al., 1997). In another study, 
glycoproteins of 5.5kDa, mainly of mannose (up to 70 %), had also been isolated, which also 
showed effects on wound healing and cells proliferation, both in vivo and in vitro (Choi et 
al., 2001). Lectin proteins from Aloe arborescence of 35 kDa, composed of 9kDa subunits 
had also been reported, which showed hemagglutinating and mitogenic effects (Winters et 
al., 1981).  In the current study, proteins extracted from A. vera gel were quantified and its 
concentration was ranged from 22.6-26 µg/ml. Automated electrophoretic analysis revealed 
the presence of proteins of molecular weight 1 and 6kD. Variability in proteins molecular 
weight in current and previous studies might be due to seasonal conditions/variations, 
techniques used to isolate proteins etc. 
In biological evaluation, immunological responses were determined both for cellular 
and humoral immune responses. Cell mediated immune responses were determined by in 
vivo lymphoproliferative response to PHA-P and carbon particle clearance assay. In vitro cell 
mediated immune responses were detected by lymphoproliferative response to Concanavalin-
A (Con-A). Humoral immune responses were quantified by antibody response to sheep red 
blood cells.  
           Results revealed significantly higher in vivo cellular immune responses in chickens 
administered with A. vera polysaccharides and proteins. During body defenses, phagocytosis 
immediately affects invading foreign materials; whereas, T cells take time to be stimulated 
and proliferated before responding to invading agent (Lamont, 1986). PHA-P is a T-cell 
mitogen, which induces proliferation of T-lymphocytes. Its injection at a particular site 
induces localized in vivo T-cell lymphoproliferation (Cheema et al., 2003). These higher 
responses in experimental groups might be due to A. vera polysaccharides (Acemannan). 
Acemannan activates macrophages to inflammatory cytokines including IL-1, IL-6 and TNF-
α (Tan and Vanitha, 2004). Acemannan also induces nitric oxide production through 
macrophage mannose receptors and activates macrophages, which cause immunomodulation 
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in chickens (Karaca et al., 1995). From these results, it can be speculated that A. vera 
polysaccharides induced cellular immune response that might play role in controlling and 
clearing the organism (Kougt et al., 1994) thus enhanced resistance against coccidiosis in 
chickens (Parmentier et al., 2001). 
Concanavalin-A was used to assess in vitro cell mediated immune responses in 
experimental and controlled chickens at 7th and 14th day post administration of A. vera  
polysaccharides and proteins. Chickens administered with A. vera polysaccharides and 
proteins showed higher lymphoproliferation responses as compared to control group. It 
indicates that T-lymphocytes contained CD4 and CD8 cells. These cells repopulated 
peripheral blood leukocytes (PBLs) during any infection and helped in immune responses 
amplification including antibody production by producing different cytokines (Qureshi et al., 
2000). This increased stimulation index in treated groups was due to direct contact of T-
lymphocytes mitogen receptors, came in direct contact with Con-A (T-cell mitogen). It 
caused lymphocytes cell division, which resulted in increased response to Con-A (Qureshi et 
al., 2000). These stimulated PBLs by Con-A, produced interleukin-1 by monocytes, which 
stimulated lymphocyte proliferation (Abbas et al., 1991).  
 In the current study, carbon particle clearance test was used as an indicator of 
phagocytic activity of reticuloendothelial system, generally measured by clearance of carbon 
particles from blood stream (Neha and Mishra, 2011). The test was performed to evaluate 
drug effects on reticuloendothelial system. It involved phagocytic cells, fixed tissues and 
mobile macrophages. These cells have an important role in particle clearance from blood 
(Ismail and Asad, 2009). Phagocytosis is a defensive mechanism, which showed its effects 
immediately after invasion of foreign particles (Lamont, 1986). Macrophages phagocytic 
activity is an important marker of immune reactivity, which can be increased by herbal 
polysaccharides (Shin et al., 2002; Moretao et al., 2003; Chen et al., 2010). 
Polysaccharide primarily target macrophages and induced immunomodulation and have 
diverse therapeutic activities. They specially bind to many cell surface receptors on 
macrophages, including Toll-like receptors, dectin-1, CD14 and CR3, which are similar to 
microbial polysaccharides binding receptors. Polysaccharides activated macrophages to 
secrete nitric oxide and many chemokines and cytokines including (IFN-γ, IL-1, IL-6, IL-8, 
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IL-12 and TNF-α).  They also increased myelopoiesis, macrophage maturation and monocyte 
release from bone marrow. There is a little information about polysaccharides structure in 
reported studies; it is therefore mostly impossible to demonstrate that how specifically 
polysaccharides influenced macrophages activity for immunomodulation (Schepetkin and 
Quinn, 2006). 
 In the current study, when India ink injected intravenously into systemic circulation of 
chickens, carbon particles were engulfed by macrophages. The clearance rate of carbon 
particles and phagocytic index was calculated. The results of present study showed 
significantly higher clearance index in control group and all the other medicated groups 
showed low clearance index values indicating less carbon particles in blood. The results of 
phagocytic index (α) showed significantly higher response in all experimental groups 
administered with A. vera polysaccharides and proteins as compared to control. Maximum 
response was observed in group A2 and B2, which were administered with A. vera 
polysaccharides and proteins (at the dose rate of 200mg/kg body weight, respectively). 
Results indicated higher phagocytic index of treated groups (at dose rate of 100 and 200 
mg/kg body weight), which might be due to reticuloendothelial system stimulation (Ismail 
and Asad, 2009; Neha and Mishra, 2011; Hajra et al., 2012).  
Humoral immune responses were calculated in terms of total immunoglobulins (Igs), 
IgG and IgM antibody titers at day 7th and 14th post primary and secondary injection of sheep 
red blood cells (RBCs) and results expressed by calculating geomean titers in experimental 
and control groups. Significantly higher total Igs, IgG and IgM titers in experimental groups 
administered either A. vera polysaccharides or proteins showed their effects on the humoral 
arms of the chicken immune response as A. vera polysaccharides/proteins might have the 
ability to enhance the immunity (Waihenya et al., 2002; Akhtar et al., 2012). Effect of A. 
vera polysaccharides to stimulate the humoral immune responses is reported in mice in some 
previous studies (Madan et al., 2008; Yu et al., 2009) as polysaccharides contained aloeride, 
a high molecular weight polysaccharide, which induced IL-6 (a potent B-cell stimulant) to 
produce antibodies (Tan and Vanitha, 2004). Present study showed consistent findings to 
those of other scientists, who reported an increased antibody titer after feeding A. vera 
against Newcastle Disease virus (Hafeez et al., 2003; Jinag et al., 2005). Present study results 
were similar to Yu et al. (2009), who concluded that A. vera polysaccharides administered 
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groups of rats showed significant increase in IgA, IgM and IgG levels. Polysaccharides also 
increased indices of spleen and thymus; and increased levels of TNF-α, IL-2 and IgG in mice 
(Chen et al., 2005). Further, highest antibody titer was observed in groups of chickens 
administered with A. vera proteins @ 300mg/kg and polysaccharides @ 200mg/kg body 
weight. Sheep RBCs act as T-dependent antigens required combined effect of macrophages, 
B and T lymphocytes (Benacerraf, 1978), which elevated the humoral immune responses in 
the current study. 
The chicken immune system contains specialized organs, cells and glands, which 
work efficiently and accurately to protect the body from invading pathogens including 
bacteria, viruses, parasites and fungi. Immune system can be divided into three basic 
subsystems viz. cellular, humoral and phagocytosis; each having different modes of action to 
prevent the body against diseases. Impaired functions of lymphoid organs are important 
indicators to demonstrate body’s ability to protect against certain diseases/disorders and can 
be expressed in terms of organ-body weight ratio (Heckert et al., 2002). Cells of the immune 
system, T and B lymphocytes, developed and differentiated in spleen and bursa (Eerola et al., 
1987). In the present study, immune organ index was calculated in terms of organ-body 
weight ratios. Experimental groups administered with A. vera  polysaccharides showed 
apparently higher per cent organ-body weight ratios as compared to control group; although, 
the difference was statistically non-significant (p>0.05) except thymus of experimental group 
A2, which showed significantly higher response as compared to control. Similar response of 
organ-body weight ratios except spleen was observed in experimental chickens administered 
with proteins.  
 Chickens of all the groups were weighed on weekly basis from 1st to 6th week of age 
and feed consumed by each group was also recorded as important parameters/indicators of 
performance of a particular group. Experimental groups showed significantly higher (p<0.05) 
weight gains as compared to control. Maximum weight gains (at 6th week of age) were 
observed in groups administered with A. vera polysaccharides and proteins. These results 
were in accordance with findings of Jinag et al. (2005), Guo et al. (2004), Mehmet et al. 
(2005) and Durrani et al. (2007). Increased body weight gain and FCR had also been 
reported in other studies (Jagadeeswaran, 2007; Durrani et al., 2008; Olupona et al., 2010); 
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however, A. vera combination with Curcuma longa showed non-significant difference in 
weight gains but numerically higher body weight gains (Mehala and Moorthy, 2008). In 
another study, Lin et al. (2005) reported non-significant difference in feed conversion ratio 
between A. vera fed chickens and control.  
In the present study, the therapeutic efficacy of A. vera polysaccharides and proteins 
against avian coccidiosis was investigated. Chickens of all the experimental and control 
groups were challenged with mixed Eimeria species (local isolates; E. tenella, E. maxima, E. 
acervulina and E. necatrix) at 14th day post administration of A. vera biomolecules.  
Significantly lower oocysts per gram of droppings in experimental groups were 
calculated as compared to control, which may be due to resistance induced by administration 
of polysaccharides and proteins. Moreover, chickens administered with A. vera biomolecules, 
(protein and polysaccharides) developed lesser lesions on the caeca and intestine, and 
showed more protection than control. Lesion score is most common method for assessing 
intestinal condition during coccidiosis (Arabkhazaeli et al., 2013). Less intestinal lesions may 
be due to the effects of A. vera on intestinal tract microflora and reduced bowel putrefaction 
that subsided/decreased inflammation (Reynolds and Dweck, 1999) or lining of intestine 
layer with A. vera biomolecules (Waihenya et al., 2002). Acemannan treated broiler birds 
showed improved intestinal microflora (Lin et al., 2005). 
Intestinal health is very important in chickens for better performance and improved 
FCR (Montagne et al., 2003). In vivo and in vitro anti parasitic properties of A. vera has been 
reported earlier. Its larvicidal and ovicidal effects against Haemonchus contortus and 
Leishmania spp. has also been documented (Dutta et al., 2008; Maphosa et al., 2010). 
Recently, Yim et al. (2011) reported that A. vera extract can be used as a safe dietary 
supplement against coccidiosis.  
 Maximum protection (70%) in polysaccharides administered chickens may be due to 
presence of Acemannan (a linear polymer containing acetylated mannose) component present 
in the A. vera, which act as immunomodulator and have antiviral activity; reduce 
opportunistic infections and stimulate wound healing (Christiaki and Florou-Paneri, 2010; 
Rodriguez et al., 2010; Darabighane et al., 2011). Further, Aloe proteins included Aloctin A 
and B, ATF 11 and salicylic acid, which have been reported to show antibacterial, anti 
91 
  
inflammatory, hemagglutinating and anti-inflammation effects (Davis and Maro, 1989; Ni 
and Tizard, 2004); and in current studies proteins administered chickens showed protection 
up to 57.5 per cent and showed lesser lesions as compared to control and more protection 
against lesions. Protection in the current study may be due to two effects of A. vera 
biomolecules; one as immunostimulation and second as wound healer (Talmadge et al., 
2004). A. vera polysaccharides contain mannose, which increase fibroblast proliferation and 
macrophages activities (Davis et al., 1989), which in turn act as wound healing agent against 
coccidiosis. Further, several carbohydrate polymers (glucomannans) present in A. vera play 
role in healing process (Shelton, 1991) and inhibit cyclooxygenase pathway resulting in 
decreased prostaglandin production from arachidonic acids (Grindlay and Reynolds, 1986). 
As a result, it acts as an analgesic, anti-inflammatory and wound healing agent (Ovodov, 
1998). 
The chickens in all experimental groups were comparatively active as compared to 
control, had normal feed and water intakes; whereas, control group chickens were 
depressed/dull with ruffled feathers and less feed and water intake; may be due to coccidial 
lesions on the intestine, which effects body metabolism due to malabsorption (Kettunen et 
al., 2001; Dalloul et al., 2006) that resulted in less feed and water intake, decreased weight 
gains (Adams et al., 1996; Jang et al., 2007). Results of present study showed similar 
response against coccidiosis in terms of higher survival percentage, reduction in oocyst 
scores, higher weight gains and improved FCR when administered with herbal complex 
(Zaman et al., 2012), sugarcane (Awais et al., 2011). 
Anticoccidial index (ACI) reflects a comprehensive ability of anticoccidial 
compounds or drugs. It was calculated by growth rate, oocyst value, survival rate and lesion 
value (You et al., 2008). According to Pablos et al. (2010), when ACI value lower than 120 
this product has no anticoccidial activity, values between 120-160 partially effective and very 
effective at ˃ 160. ACI values calculated in present study for A. vera polysaccharides 
administered groups were A1 159.75, A2 239.63 and A3 195.31.  While results of proteins 
administered groups were B1 103.26, B2 172.21 and B3 162.37. So A. vera polysaccharides 
and proteins at the dose rate of 200 and 300 mg/kg body weight proved very effective against 
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coccidiosis. Results of present study are consistent with the findings of Pablos et al. (2010), 
which showed higher ACI values in infected chickens when administered with maslinic acid. 
Organ-body weight ratios of immune organs including spleen, thymus, caecal tonsils 
and bursa of fabricius were calculated on day 12th post challenge with mixed Eimeria species. 
All the experimental groups showed statistically similar organ-body weight ratios (p>0.05) 
except spleen; spleen of control chickens showed significantly higher organ-body weight 
ratios as compared to experimental groups administered with A. vera polysaccharides. 
Variable results on the lymphoid organs due to coccidiosis has been reported including 
adverse effect (Akhtar and Zafar, 2003), no effect (Augustine and Thomas, 1979) or 
increased in their weight (Venkatratnam et al., 1985). On the other hand, A. vera protein 
administered groups showed significantly higher spleen to body weight ratio; this may be due 
to cellular infiltration and spleen hypertrophy due to coccidiosis (Bettsille, 1986). 
 Results of current study indicated that A. vera bio-molecules, polysaccharides and 
proteins, have the potential to stimulate the humoral and cellular arms of the immune 
responses that may release cytokines to induce localized inflammatory reactions. This in turn 
increased vascular permeability; caused vasodilation, activation and accumulation of 
macrophages; enhanced phagocytic activity and more lytic enzyme production for 
destruction of pathogen(s) (Dashputre and Naikwade, 2010; Neha and Mishra, 2011).  
93 
  
Conclusions  
Following conclusions were drawn from the present study. 
1. A. vera contains bio-molecules including polysaccharides and proteins, which had 
potential to act as biological response modifiers in broiler chickens. 
2. A. vera polysaccharides and proteins administered chickens showed significantly higher 
cell mediated and humoral immune responses as compared to control. 
3. Production performance in terms of weekly weight gains and FCR were better in 
chickens administered with polysaccharides and proteins at dose rates of 300 mg/kg body 
weight. 
4. In challenge experiments, experimental groups administered with A. vera biomolecules 
showed higher per cent protection; statistically higher (p<0.05) daily weight gains, lower 
(p<0.05) oocysts counts and lesion scores as compared to chickens in control groups. 
5. Chickens of experimental groups administered with A. vera biomolecules showed higher 
anticoccidial indices as compared to those of control groups. 
6. Organ-body weight ratios of all lymphoid organs except spleen were statistically similar 
in both control and A. vera biomolecules administered chickens. 
 On the whole, it was concluded that A. vera derived biomolecules have the potential 
to be used as immunotherapeutic agents in poultry and can be commercialized. 
Recommendations 
 Further studies are needed on field evaluation of A. vera derived biomolecules and to 
demonstrate their possible mechanism(s) of action for their scientific validation. Further, 
feasibility should also be made for the commercialization of these biomolecules for their 
efficient use as biological response modifiers in poultry. 
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CHAPTER 6   
SUMMARY   
 
Current study focused to isolate the A. vera polysaccharides and proteins and to 
evaluate their efficacy as biological response modifiers followed by their immunotherapeutic 
effects against avian coccidiosis in industrial broiler chickens. Purified polysaccharides from 
A. vera were analyzed by using high performance liquid chromatography (HPLC). Results 
showed presence of three different monosaccharides including maltose, glucose and mannose 
in hydrolyzed solution at retention times 9.423, 11.080 and 12.55, respectively. Proteins 
extracted from A. vera were quantified by Bradford assay and concentration was ranged from 
22.6-26 µg/ml. The isolated proteins were subjected to automated electrophoretic analysis, 
which showed presence of proteins of molecular weight 1 and 6kD. 
For immunological evaluation of A. vera polysaccharides and proteins, cell mediated 
and humoral immune responses were determined. Cell mediated immune responses were 
calculated by in vivo lymphoproliferative response to PHA-P and carbon particle clearance 
assay. In vitro cell mediated immune responses were detected by lymphoproliferative 
response to Concanavalin-A (Con-A). Humoral immune responses were calculated by 
antibody response to sheep red blood cells. Results of in vivo lymphoproliferative response to 
PHA-P showed significantly higher (p<0.05) response in chickens administered with A. vera 
polysaccharides and proteins as compared to control. In polysaccharides administered group, 
chickens of group A2 (at dose rate of 200mg/kg body weight) revealed a significantly higher 
(p<0.05) response as compared to control at 24, 48 and 72 hours post PHA-P injection. 
Chickens of protein administered groups showed significantly higher toe-web swelling for 
group B2 (at dose rate of 200mg/kg body weight). Lymphoblastogenic response to Con-A at 
7th and 14th day post administration of A. vera  polysaccharides and proteins administered 
chickens showed higher response than control.  
Carbon particle clearance assay showed significantly higher clearance index in 
control group and all the other medicated groups showed low clearance index values 
indicating less carbon particles in blood. The results of phagocytic index showed 
significantly higher response in all three medicated groups as compared to control. Maximum 
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response was observed in group A2 and B2, which were administered with A. vera 
polysaccharides and proteins, respectively (at the dose rate of 200mg/kg body weight).  
Humoral immune response were calculated in terms of total immunoglobulins (Igs), 
IgG and IgM antibody titers at day 7th and 14th post primary and secondary injection of sheep 
red blood cells. Results were expressed by calculating geomean titers in experimental and 
control groups. Significantly higher total Igs, IgG and IgM titers in experimental groups 
administered either A. vera polysaccharide or proteins showed their effects on the humoral 
arms of the chicken immune system. Results indicated that A. vera polysaccharides/proteins 
may have the ability to enhance the immunity. 
Experimental groups administered with A. vera  polysaccharides showed apparently 
higher per cent organ-body weight ratios as compared to control group; although, the 
difference was statistically non-significant (p>0.05) except thymus of experimental group A2, 
which showed significant response as compared to control. Almost similar response of 
organ-body weight ratios was observed in experimental chickens administered with protein. 
Chickens of all the groups were weighed (week 1st to 6th) and feed consumed by each group 
recorded as important parameters/indicators of performance of a particular group. 
Experimental groups showed significantly higher (p<0.05) weight gains as compared to 
control. Maximum weight gains at 6th week were observed in groups administered with A. 
vera polysaccharides and proteins. All experimental groups administered with A. vera 
polysaccharides and proteins showed better FCR as compared to control.  
In this study, therapeutic efficacy of A. vera polysaccharides and proteins were 
checked against avian coccidiosis. Chickens of all the experimental and control groups were 
challenged with mixed Eimeria species local isolates. Maximum protection of 70% and 
57.5% were observed in polysaccharides and proteins administered groups (at the dose rate 
of 200mg/kg body weight) respectively. Significantly lower oocysts per gram of droppings 
and lesion scores were calculated in both polysaccharides and proteins administered groups 
as compared to control. 
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Anticoccidial index (ACI) values calculated for A. vera polysaccharides were 159.75, 
239.63 and 195.31 for groups A1, A2 and A3, respectively; and for proteins 103.26, 172.26 and 
162.37 for group B1, B2 and B3, respectively. It was concluded that A. vera biomolecules, 
polysaccharides and proteins, have the potential to be used against coccidiosis. 
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ANNEXURES 
Annexure I 
Zinc Sulphate Floatation Solution 
Reagents 
Zinc Sulphate         386 gm 
Distilled water       1000 ml 
Specific gravity      1.200-1.300 
 
Annexure II 
Different Eimeria species infecting chickens (Reid and Long, 1979) 
Species Region Infected 
 
Average oocyst size 
(l x w, μm) 
E. tenella Caeca 22.0 x 19.0 
E. acervulina Duodenum 18.3 x 14.6 
E. brunetti Lower intestine, rectum 24.6 x 18.8 
E. maxima Upper intestine, ileum 30.5 x 20.7 
E. mitis Upper intestine 16.2 x 16.0 
E. praecox Duodenum, upper jejunum 21.3 x 17.1 
E. necatrix Mid intestine, Cecae 20.4 x 17.2 
 
Annexure III 
Vaccination Schedule adopted to immunize the experimental and control chickens   
Age of the chick 
(Days) 
Vaccine Route 
adopted 
6 Newcastle disease vaccine (Merial®, France) Eye drop 
10 Infectious bursal disease vaccine (Merial®, France) Oral 
17 HPS vaccine (Sanna Labs., Pakistan) S/C 
20 Infectious bursal disease vaccine (Booster) 
(Merial®, France) 
Oral 
22 Newcastle disease vaccine (Booster) (Merial®, France) Oral 
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Annexure IV: Chromatograms of standard monosaccharide solutions 
 
 
a. Chromatogram of D-Arabinose 
 
b. Chromatogram of Galactose 
 
c. Chromatogram of D-Xylose 
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d. Chromatogram of Maltose 
 
 
e. Chromatogram of Mannose 
 
 
f. Chromatogram of Fructose 
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g. Chromatogram of Glucose 
 
 
h.  Chromatogram of Melezitose 
 
 
 
 
 
 
 
 
